Capture-Collapse Heterocyclization: 1,3-Diazepanes by C-N Reductive Elimination from Rhodacyclopentanones

Niall G. McCreanor,[§] Steven Stanton, [§] and John F. Bower^{*§}

[§]School of Chemistry, University of Bristol, Bristol, BS8 1TS, UK

Supporting Information

Table of Contents

General Experimental Details	S1
Experimental Procedures and Data	S2
General Procedures	S2
"Capture-Collapse" Substrates and Products	S3
Selected Reaction Optimization Tables	\$56
Further Oxidative Insertion Regioselectivity Experiments	S59
Copies of ¹ H and ¹³ C NMR spectra for novel compounds	S65
References	S144

General Experimental Details. Starting materials sourced from commercial suppliers were used as received unless otherwise stated. Dry solvents, where necessary, were obtained by distillation using standard procedures or by passage through a column of anhydrous alumina using equipment from Anhydrous Engineering based on the Grubb's design.¹ The removal of solvents in vacuo was achieved using both a Büchi rotary evaporator (bath temperatures up to 40 °C) at a pressure of either 15 mmHg (diaphragm pump) or 0.1 mmHg (oil pump), as appropriate, and a high vacuum line at r.t.. Reactions requiring anhydrous conditions were run under an atmosphere of dry nitrogen or argon; glassware was either flame dried immediately prior to use or placed in an oven (200 °C) for at least 2 h and allowed to cool either in a desiccator or under an atmosphere of nitrogen or argon; liquid reagents, solutions or solvents were added via syringe through rubber septa. Commercially available Merck Kieselgel 60F254 aluminium backed plates were used for TLC analysis. Visualization was achieved by either UV fluorescence or basic KMnO₄ solution and heat. Flash column chromatography (FCC) was performed using silica gel (Aldrich 40-63 µm, 230-400 mesh). The crude material was applied to the column as a solution in the corresponding solvent system, CH₂Cl₂, or by pre-adsorption onto silica, as appropriate. Melting points were determined using a Reichert melting point table and temperature controller and are uncorrected. Infra-red spectra were recorded in the range 4000-600 cm⁻¹ on a Perkin Elmer Spectrum either as neat films or solids compressed onto a diamond window. Abbreviations used are: w (weak), m (medium) or s (strong). NMR spectra were recorded using either a Varian 400 MHz or JOEL ECS 400 MHz spectrometer. Chemical shifts (δ) are quoted in parts per million (ppm), coupling constants (J) are given in Hz to the nearest 0.5 Hz. Other abbreviations used are s (singlet), d (doublet), t (triplet), m (multiplet) and br (broad). ¹H and ¹³C NMR spectra were referenced to the appropriate residual solvent peak. Assignments of ¹H NMR and ¹³C NMR signals were made, where possible, using COSY, DEPT¹³⁵, HSQC, HMBC and NOE experiments. Where mixtures of products (e.g. diastereomers, regioisomers or 8 vs 9) have been isolated together, they have been characterized separately where possible. Numbering systems for NMR signal assignments are specified on the structure and are not related to those used for the compound names. Mass spectra were determined by the University of Bristol mass spectrometry service by either electron impact (EI⁺) or chemical ionization (CI⁺) using a Fisons VG Analytical Autospec spectrometer, or by electrospray ionization (ESI⁺) using a Brüker Daltonics Apex IV spectrometer. Chiral SFC was performed using the racemate as a standard on an Agilent 1290 Infinity system equipped with a quaternary pump, diode array detector and column thermostat under the conditions specified in each case.

General procedure A for the formation of ureas from isocyanates

To a solution of amine (110 mol%) and NEt₃ (200 mol%) in CH₂Cl₂ (0.3 M) at 0 °C was added the specified isocyanate (100 mol%). The reaction mixture was warmed to r.t. and stirred for the specified time (1-18 h). The solution was diluted with CH₂Cl₂ (3 mL/mmol) and washed with water (5 mL/mmol), aq. 1 M HCl (5 mL/mmol), sat. aq. NaHCO₃ (5 mL/mmol) and brine (5 mL/mmol). The organic layer was dried over Na₂SO₄ and concentrated *in vacuo*. The product was purified by flash column chromatography, under the conditions noted, to afford the title compound.


General procedure B for the carbonylative cyclization of cyclopropylureas

An oven dried reaction tube, fitted with a magnetic stirrer, was charged with benzoic acid (15 mol%), the specified Rh pre-catalyst (3.5-10 mol%), PPh₃ (7.0-20 mol%) and urea substrate (100 mol%). The tube was fitted with a rubber septum and purged with argon. Argon sparged anhydrous 1,2-dichlorobenzene (0.2 M) was added *via* syringe before aging the catalyst for *ca*. 5 minutes. The reaction tube was purged with CO and the reaction mixture was sparged for 10 seconds. The reaction was heated at the specified temperature (90-100 °C) under a CO atmosphere until complete consumption of the starting material was observed by thin layer chromatography (23-92 h). The mixture was cooled to r.t., concentrated *in vacuo* and purified by flash column chromatography, under the conditions noted, to afford the target heterocycle.

<u>General procedure C</u> for the deprotection/urea formation of Boc-protected cyclopropylamines


To a solution of Boc-protected cyclopropylamine (100 mol%) in CH_2Cl_2 (1 M) was added trifluoroacetic acid (1000 mol%) and the reaction was stirred at r.t. for 30 minutes. The reaction mixture was concentrated *in vacuo*. The resulting trifluoroacetate salt and NEt₃ (250 mol%) were dissolved in CH_2Cl_2 (0.3 M) before adding benzyl isocyanate (95 mol%). The reaction was stirred at r.t. for the specified time before being diluted with CH_2Cl_2 (5 mL/mmol). The solution was washed with water (5 mL/mmol), aq. 1 M HCl (5 mL/mmol), sat. aq. NaHCO₃ (5 mL/mmol) and brine (5 mL/mmol), dried over Na₂SO₄ and concentrated *in vacuo*. Purification by flash column chromatography, under the conditions noted, provided the target compound.

1,3-Dibenzyl-1-cyclopropylurea (5a)



General procedure A: *N*-Benzylcyclopropanamine² (1.77 g, 11.0 mmol) and benzyl isocyanate (1.24 mL, 10.0 mmol) were employed. The crude mixture was purified by silica gel column chromatography (50% EtOAc/hexane) to yield the title compound **5a** (2.26 g, 81%) as a colorless solid; m.p.: 80-82 °C (CH₂Cl₂/hexane); v_{max} / cm^{-1} : 3369 (s), 1635 (s), 1504 (s), 1285 (m), 1230 (m); ¹H NMR (CDCl₃, 400 MHz): δ 7.35-7.21 (10H, m, 2 × C**6**-<u>H</u>, 2 × C**7**-<u>H</u>, C**8**-<u>H</u>, 2 × C**11**-<u>H</u>, 2 × C**12**-<u>H</u> and C**13**-<u>H</u>), 5.61 (1H, t, *J* = 5.5 Hz, N<u>H</u>), 4.58 (2H, s, C**9**-<u>H</u>₂), 4.50 (2H, d, *J* = 5.5 , Hz, C**4**-<u>H</u>₂), 2.35 (1H, tt, *J* = 7.0, 4.0 Hz, C**2**-<u>H</u>), 0.78-0.74 (4H, m, C**1**-<u>H</u>₂); ¹³C NMR (CDCl₃, 100 MHz): δ 159.1 (C**3**), 139.8 (C**5**), 139.1 (C**10**), 128.7, 128.5, 128.0, 127.5, 127.3, 127.0 (C**6**, C**7**, C**8**, C**11**, C**12** and C**13**), 50.6 (C**9**), 44.9 (C**4**), 27.8 (C**2**), 8.8 (C**1**); HRMS: (ESI⁺) Calculated for C₁₈H₂₁N₂O: 281.1648. Found [M + H]⁺: 281.1662.

1,3-Dibenzyl-3,6-dihydro-1*H*-1,3-diazepine-2,7-dione (8a) *and* 1,3-Dibenzyl-1,3-diazepane-2,4-dione (9a)




General Procedure B: Urea **5a** (53.2 mg, 0.15 mmol) and $[Rh(cod)_2]BARF$ (3.5 mol%) were employed and the reaction was stirred for 24 h at 100 °C. The crude mixture was purified by silica gel column chromatography (25% EtOAc/hexane) to yield the title compound **8a** (37.5 mg, 82%) as a yellow oil. Analysis of the crude reaction mixture by ¹H NMR revealed a 20:1 (**8a:9a**) mixture of products. An analytical sample of **9a** was also isolated for characterisation.

Data for major compound **8a**; v_{max} / cm^{-1} : 1699 (s), 1647 (s), 1406 (s), 1395 (s), 1212 (s); ¹H NMR (CDCl₃, 400 MHz): δ 7.30-7.21 (8H, m, 2 × C9-<u>H</u>, C10-<u>H</u>, 2 × C13-<u>H</u>, 2 × C14-<u>H</u>, C15-<u>H</u>), 7.05-7.03 (2H, m, 2 × C8-<u>H</u>), 6.03 (1H, d, *J* = 7.0 Hz, C5-<u>H</u>), 5.54 (1H, dt, *J* = 7.0, 7.0 Hz, C4-<u>H</u>), 5.05 (2H, s, C11-<u>H</u>₂), 4.73 (2H, s, C6-<u>H</u>₂), 3.08 (2H, d, *J* = 7.0 Hz, C3-<u>H</u>₂); ¹³C NMR (CDCl₃, 100 MHz): δ 170.0 (C2), 153.9 (C1), 137.6 (C12), 136.1 (C7), 130.3 (C5), 128.7.

128.4, 128.1, 127.8, 127.6, 127.3 (C8, C9, C10, C13, C14, C15), 112.7 (C4), 53.0 (C6), 47.9 (C11), 35.0 (C3); HRMS: (ESI⁺) Calculated for C₁₉H₁₈N₂NaO₂: 329.1260. Found [M + Na]⁺: 329.1249. *The structure of this compound was confirmed by 2D NMR. Key HMBC correlations are included on the compound structure above.*


Data for minor compound **9a**; v_{max} / cm^{-1} : 1694 (s), 1656 (s), 1421 (s), 1214 (s), 1158 (s); ¹H NMR (CDCl₃, 400 MHz): δ 7.38-7.23 (8H, m, 2 × C**9**-<u>H</u>, C**10**-<u>H</u>, 2 × C**13**-<u>H</u>, 2 × C**14**-<u>H</u>, C**15**-<u>H</u>), 7.09-7.06 (2H, m, 2 × C**8**-<u>H</u>), 4.94 (2H, s, C**11**-<u>H</u>₂), 4.60 (2H, s, C**6**-<u>H</u>₂), 3.18 (2H, t, *J* = 7.0 Hz, C**5**-<u>H</u>₂), 2.54 (2H, t, *J* = 7.0 Hz, C**3**-<u>H</u>₂), 1.86 (2H, tt, *J* = 7.0, 7.0 Hz, C**4**-<u>H</u>₂); ¹³C NMR (CDCl₃, 100 MHz): δ 171.3 (C**2**), 157.6 (C**1**), 137.8 (C**12**), 136.7 (C**7**), 128.8, 128.7, 128.5, 127.8, 127.5 (C**8**, C**9**, C**10**, C**13**, C**14**, C**15**), 51.8 (C**6**), 46.8 (C**11**), 45.6 (C**5**), 33.7 (C**3**), 25.7 (C**4**); HRMS: (ESI⁺) Calculated for C₁₉H₂₀N₂NaO₂: 331.1417. Found [M + Na]⁺: 331.1416. *The structure of this compound was confirmed by 2D NMR. Key HMBC correlations are included on the compound structure above.*

1-Benzyl-3-butyl-1-cyclopropylurea (5b)



General procedure A: *N*-Benzylcyclopropanamine² (1.77 g, 11.0 mmol) and butyl isocyanate (1.12 mL, 10.0 mmol) were employed. This crude mixture was purified by silica gel column chromatography (30% EtOAc/hexane) to yield the title compound **5b** (2.43 g, 99%) as a colorless oil; v_{max} / cm^{-1} : 3377 (m), 1638 (s), 1513 (s), 1283 (s), 1269 (s); ¹H NMR (CDCl₃, 400 MHz): δ 7.27-7.16 (5H, m, 2 × C10-H, 2 × C11-H, C12-H), 5.31 (1H, t, *J* = 5.5 Hz, NH), 4.51 (2H, s, C8-H₂), 3.26 (2H, td, *J* = 7.0, 5.5 Hz, C4-H₂), 2.28 (1H, tt, *J* = 6.5, 4.0 Hz, C2-H), 1.53-1.46 (2H, m, C5-H₂), 1.38-1.29 (2H, m, C6-H₂), 0.91 (3H, t, *J* = 7.5 Hz, C7-H₃), 0.76-0.67 (4H, m, 4 × C1-H); ¹³C NMR (CDCl₃, 100 MHz): δ 159.0 (C3), 139.2 (C9), 128.3, 128.8, 126.8 (C10, C11, C12), 50.3 (C8), 40.4 (C4), 32.5 (C5), 27.7 (C2), 20.1 (C6), 13.8 (C7), 8.6 (C1); HRMS: (ESI⁺) Calculated for C₁₅H₂₂N₂NaO: 269.1624. Found [M + Na]⁺: 269.1629.

3-Benzyl-1-butyl-3,6-dihydro-1*H*-1,3-diazepine-2,7-dione (8b) *and* 1-Benzyl-3-butyl-1,3-diazepane-2,4-dione (9b)




General Procedure B: Urea **5b** (37.0 mg, 0.15 mmol) and [Rh(cod)₂]BARF (5.0 mol%) were employed and the reaction was stirred for 24 h at 100 °C. The crude mixture was purified by silica gel column chromatography (20% EtOAc/hexane) to yield the title compound **8b** (35.2 mg, 85%) as a yellow oil. Analysis of the crude reaction mixture by ¹H NMR revealed a 20:1 (**8b:9b**) mixture of products. The minor product **9b** was not isolated.

Data for major compound **8b**: v_{max} / cm^{-1} : 2958 (m), 1698 (s), 1645 (s), 1407 (s), 1214 (s); ¹H NMR (CDCl₃, 400 MHz): δ 7.36-7.26 (5H, m, 2 × C**8**-<u>H</u>, 2 × C**9**-<u>H</u>, C**10**-<u>H</u>), 6.10 (1H, d, *J* = 7.0 Hz, C**5**-<u>H</u>), 5.52 (1H, dt, *J* = 7.0, 7.0 Hz, C**4**-<u>H</u>), 4.79 (2H, s, C**6**-<u>H</u>₂), 3.80 (2H, t, *J* = 7.0 Hz, C**11**-<u>H</u>₂), 2.99 (2H, d, *J* = 7.0 Hz, C**3**-<u>H</u>₂), 1.55 (2H, tt, *J* = 7.0, 7.0 Hz, C**12**-<u>H</u>₂), 1.27 (2H, tq, *J* = 7.0, 7.0 Hz, C**13**-<u>H</u>₂), 0.90 (3H, t, *J* = 7.0 Hz, C**14**-<u>H</u>₃); ¹³C NMR (CDCl₃, 100 MHz): δ 170.1 (C**2**), 154.4 (C**1**), 136.6 (C**7**), 130.5 (C**5**), 128.8, 127.9, 127.8 (C**8**, C**9**, C**10**), 113.0 (C**4**), 53.2 (C**6**), 45.4 (C**11**), 35.2 (C**3**), 30.4 (C**12**), 20.1 (C**13**), 13.8 (C**14**); HRMS: (ESI⁺) Calculated for C₁₆H₂₀N₂NaO₂: 295.1417. Found [M + Na]⁺: 295.1421.

Data for minor compound **9b**: *Characteristic signals only*: ¹H NMR (CDCl₃, 400 MHz): δ 4.66 (2H, s, C**6**-<u>H</u>₂), 3.75 (2H, t, *J* = 7.0 Hz, C**11**-<u>H</u>₂), 3.36 (2H, t, *J* = 7.0 Hz, C**5**-<u>H</u>₂), 2.50 (2H, t, *J* = 7.0 Hz, C**3**-<u>H</u>₂); HRMS: (ESI⁺) Calculated for C₁₆H₂₂N₂NaO₂: 297.1573. Found [M + Na]⁺: 297.1575.


1-Benzyl-1-cyclopropyl-3-phenylurea (5c)



General procedure A: *N*-Benzylcyclopropanamine² (1.77 g, 11.0 mmol) and phenyl isocyanate (1.09 mL, 10.0 mmol) were employed. The crude mixture was purified by column chromatography (30% EtOAc/hexane) to yield the title compound **5c** (2.54 g, 95%) as a colorless oil; v_{max} / cm^{-1} : 3431 (m), 3355 (m), 1659 (s), 1595 (s), 1522 (s), 1499 (s), 1440 (s),

1237 (s); ¹H NMR (CDCl₃, 400 MHz): δ 7.49 (2H, d, *J* = 7.5 Hz, 2 × C5-<u>H</u>), 7.37-7.24 (8H, m, N<u>H</u>, 2 × C6-<u>H</u>, 2 × C10-<u>H</u>, 2 × C11-<u>H</u>, C12-<u>H</u>), 7.05 (1H, t, *J* = 7.5 Hz, C7-<u>H</u>), 4.64 (2H, s, C8-<u>H</u>₂), 2.53 (1H, tt, *J* = 7.0, 4.0 Hz, C2-<u>H</u>), 0.97-0.88 (4H, m, 4 × C1-<u>H</u>); ¹³C NMR (CDCl₃, 100 MHz): δ 156.1 (C3), 139.0 (C9), 138.6 (C10), 128.9 (C6), 128.5, 127.9, 127.1 (C10, C11, C12), 123.0 (C7), 119.5 (C5), 50.4 (C8), 28.1 (C2), 9.0 (C1); HRMS: (ESI⁺) Calculated for C₁₇H₁₈N₂NaO: 289.1311. Found [M + Na]⁺: 289.1306.

3-Benzyl-1-phenyl-3,6-dihydro-1*H*-1,3-diazepine-2,7-dione (8c) *and* 1-Benzyl-3-phenyl-1,3-diazepane-2,4-dione (9c)




General Procedure B: Urea **5c** (40.0 mg, 0.15 mmol) and $[Rh(cod)_2]BARF (7.5 mol%)$ were employed and the reaction was stirred for 70 h at 100 °C. The crude mixture was purified by column chromatography (15-25% EtOAc/hexane) to yield the title compound **8c** (12.2 mg, 28%) as a yellow oil. Analysis of the crude reaction mixture by ¹H NMR revealed a 5:1 (**8c:9c**) mixture of products. The minor product **9c** was not isolated.

Data for major compound **8c**: v_{max} / cm^{-1} : 2987 (s), 1705 (s), 1652 (s), 1403 (s), 1392 (s), 1226 (s); ¹H NMR (CDCl₃, 400 MHz): δ 7.45-7.19 (10H, m, 2 × C**8**-<u>H</u>, 2 × C**9**-<u>H</u>, C**10**-<u>H</u>, 2 × C**12**-<u>H</u>, 2 × C**13**-<u>H</u>, C**14**-<u>H</u>), 6.26 (1H, d, *J* = 7.0 Hz, C**5**-<u>H</u>), 5.66 (1H, dt, *J* = 7.0, 7.0 Hz, C**4**-<u>H</u>), 4.81 (2H, s, C**6**-<u>H</u>₂), 3.17 (2H, d, *J* = 7.0 Hz, C**3**-<u>H</u>₂); ¹³C NMR (CDCl₃, 100 MHz): δ 170.5 (C**2**), 153.7 (C**1**), 138.8 (C**11**), 136.4 (C**7**), 130.8 (C**5**), 129.1, 128.8, 128.5, 128.3, 128.1, 128.0 (C**8**, C**9**, C**10**, C**12**, C**13**, C**14**), 113.3 (C**4**), 53.5 (C**6**), 35.2 (C**3**); HRMS: (ESI⁺) Calculated for C₁₈H₁₆N₂NaO₂: 315.1104. Found [M + Na]⁺: 315.1092.


Data for minor compound **9c**: *Characteristic signals only*: ¹H NMR (CDCl₃, 400 MHz): δ 3.26 (2H, t, J = 7.0 Hz, C**5**-<u>H</u>₂).

1-Benzyl-3-cyclohexyl-1-cyclopropylurea (5d)



General procedure A: *N*-Benzylcyclopropanamine² (1.77 g, 11.0 mmol) and cyclohexyl isocyanate (1.28 mL, 10.0 mmol) were employed. The crude mixture was purified by column chromatography (30% EtOAc/hexane) to yield the title compound **5d** (2.15 g, 79%) as a colorless solid: m.p. 60-63 °C (CHCl₃); v_{max} / cm⁻¹: 3366 (m), 1643 (s), 1506 (s), 1452 (s), 1256 (s); ¹H NMR (CDCl₃, 400 MHz): δ 7.23-7.13 (5H, m, 2 × C7-<u>H</u>, 2 × C8-<u>H</u>, C9-<u>H</u>), 5.18 (1H, d, *J* = 8.0 Hz, N<u>H</u>), 4.48 (2H, s, C5-<u>H</u>₂), 3.67 (1H, m, C4-<u>H</u>), 2.25 (1H, tt, *J* = 6.5, 4.0 Hz, C2-<u>H</u>), 1.94-1.90 (2H, m, 2 × cyclohexyl C<u>H</u>), 1.68-1.62 (2H, m, 2 × cyclohexyl C<u>H</u>), 1.55 (1H, m, 1 × cyclohexyl C<u>H</u>), 1.39-1.28 (2H, m, 2 × cyclohexyl C<u>H</u>), 1.19-1.08 (3H, m, 3 × cyclohexyl C<u>H</u>), 0.73-0.64 (4H, m, 4 × C1-<u>H</u>); ¹³C NMR (CDCl₃, 100 MHz): δ 158.2 (C3), 139.2 (C6), 128.3, 127.8, 126.8 (C7, C8, C9), 50.3 (C5), 49.1 (C4), 33.8 (cyclohexyl <u>C</u>H₂), 27.6 (C2), 25.7 (cyclohexyl <u>C</u>H₂), 24.9 (cyclohexyl <u>C</u>H₂), 8.6 (C1); HRMS: (ESI⁺) Calculated for C₁₇H₂₄N₂NaO: 295.1781. Found [M + Na]⁺: 295.1779.

3-Benzyl-1-cyclohexyl-3,6-dihydro-1*H*-1,3-diazepine-2,7-dione (8d) *and* 1-Benzyl-3-cyclohexyl-1,3-diazepane-2,4-dione (9d)




General Procedure B: Urea **5d** (40.9 mg, 0.15 mmol) and [Rh(cod)₂]BARF (7.5 mol%) were employed and the reaction was stirred for 24 h at 100 °C. The crude mixture was purified by column chromatography (20% EtOAc/hexane) to yield the title compound **8d** (31.0 mg, 69%) as a yellow oil. Analysis of the crude reaction mixture by ¹H NMR revealed a 23:1 (**8d**:**9d**) mixture of products. The minor product **9d** was not isolated.

Data for major compound **8d**: v_{max} / cm⁻¹: 2928 (s), 1695 (s), 1648 (s), 1406 (s), 1394 (s), 1223 (s), 1049 (s); ¹H NMR (CDCl₃, 400 MHz): δ 7.36-7.24 (5H, m, 2 × C**8**-<u>H</u>, 2 × C**9**-<u>H</u>, C**10**-<u>H</u>), 6.09 (1H, d, *J* = 7.0 Hz, C**5**-<u>H</u>), 5.55 (1H, dt, *J* = 7.0, 7.0 Hz, C**4**-<u>H</u>), 4.77 (2H, s, C**6**-<u>H</u>₂), 4.14

(1H, tt, J = 12.0, 3.5 Hz, C11-<u>H</u>), 2.93 (2H, d, J = 7.0 Hz, C3-<u>H</u>₂), 2.08-1.98 (2H, m, 2 × C12-<u>H</u>), 1.81 1.63 (5H, m, 2 × C12-<u>H</u>, 2 × C13-<u>H</u>, 1 × C14-<u>H</u>), 1.38-1.11 (3H, m, 2 × C13-<u>H</u>, 1 × C14-<u>H</u>); ¹³C NMR (CDCl₃, 100 MHz): δ 17.5 (C2), 153.9 (C1), 136.5 (C7), 130.3 (C5), 128.8, 127.9, 127.8 (C8, C9, C10), 114.3 (C4), 57.5 (C11), 52.7 (C6), 35.4 (C3), 29.9 (C12), 26.3 (C13), 25.4 (C14); HRMS: (ESI⁺) Calculated for C₁₈H₂₂N₂NaO₂: 321.1573. Found [M + Na]⁺: 321.1568.


Data for minor compound **9d**: *Characteristic signals only*: ¹H NMR (CDCl₃, 400 MHz): δ 4.64 (2H, s, C**6**-<u>H</u>₂).

1-Benzyl-1-cyclopropylurea (5e)



The title compound was prepared following the literature procedure.³ In a round bottom flask containing a stirrer bar, *N*-benzylcyclopropanamine² (1.47 g, 10.0 mmol) was suspended in water (40 mL) and conc. HCl (0.84 mL, 10.0 mmol) was added. Upon stirring, a solution of KOCN (1.22 g, 15.0 mmol) in water (40 mL) was added. The mixture was stirred at r.t. for 36 h, during which time a colorless precipitate was formed. The precipitate was collected by suction filtration and the cake was purified by recystallization (CH₂Cl₂/hexane) to yield the title compound **5e** (712 mg, 37%) as colorless needles; m.p. 96-98 °C (CH₂Cl₂/hexane); v_{max} / cm⁻¹: 3484 (m), 3455 (m), 3150 (m), 1646 (s), 1591 (s), 1413 (s), 1028 (s); ¹H NMR (CDCl₃, 400 MHz): δ 7.33-7.22 (5H, m, 2 × C**6**-H, 2 × C**7**-H, C**8**-H), 5.24 (2H, br. s, NH₂), 4.55 (2H, s, C**4**-H₂), 2.44 (1H, m, C**2**-H), 0.83-0.75 (4H, m, 4 × C**1**-H); ¹³C NMR (CDCl₃, 100 MHz): δ 160.1 (C**3**), 138.7 (C**5**), 128.4, 127.7, 127.0 (C**6**, C**7**, C**8**), 50.1 (C**4**), 28.6 (C**2**), 8.5 (C**1**); HRMS: (ESI⁺) Calculated for C₁₁H₁₄N₂NaO: 213.0998. Found [M + Na]⁺: 213.1006.

3-Benzyl-3,6-dihydro-1*H*-1,3-diazepine-2,7-dione (8e) *and* 1-Benzyl-1,3- diazepane-2,4dione (9e)




General Procedure B: Urea **5e** (28.5 mg, 0.15 mmol) and $[Rh(cod)_2]BARF (5.0 mol%)$ were employed and the reaction was stirred for 72 h at 100 °C. The crude mixture was purified by column chromatography (45% EtOAc/hexane) to yield the title compound **8e** (17.5 mg, 54%) as a beige oil. Analysis of the crude reaction mixture by ¹H NMR revealed an 8:1 (**8e:9e**) mixture of products. The minor product **9e** was not isolated.

Data for major compound **8e**: v_{max} / cm^{-1} : 3215 (m), 2987 (s), 1653 (s), 1412 (s), 1388 (s), 1260 (s), 1075 (s); ¹H NMR (CDCl₃, 400 MHz): δ 7.50 (1H, br. s, N<u>H</u>), 7.38-7.24 (5H, m, 2 × C**8**-<u>H</u>, 2 × C**9**-<u>H</u>, C**10**-<u>H</u>), 6.09 (1H, d, *J* = 7.5 Hz, C**5**-<u>H</u>), 5.42 (1H, dt, *J* = 7.5, 7.0 Hz, C**4**-<u>H</u>), 4.78 (2H, s, C**6**-<u>H</u>₂), 3.06 (2H, d, *J* = 7.0 Hz, C**3**-<u>H</u>₂); ¹³C NMR (CDCl₃, 100 MHz): δ 171.1 (C**2**), 151.2 (C**1**), 136.2 (C**7**), 130.8 (C**5**), 128.9, 128.0, 127.9 (C**8**, C**9**, C**10**), 110.4 (C**4**), 52.6 (C**6**), 34.3 (C**3**); HRMS: (ESI⁺) Calculated for C₁₂H₁₂N₂NaO₂: 239.0790. Found [M + Na]⁺: 239.0787.

Data for minor compound **9e**: *Characteristic signals only*: ¹H NMR (CDCl₃, 400 MHz): δ 3.41 (2H, t, J = 7.0 Hz, C**5**-<u>H</u>₂).


N-Butylcyclopropanamine



A solution of cyclopropylamine (8.31 mL, 120 mmol), butyraldehyde (9.01 mL, 100 mmol) and NaHCO₃ (12.6 g, 150 mmol) in MeOH (100 mL) was heated at reflux for 24 h. The reaction mixture was cooled to 0 °C and NaBH₄ (4.73 g, 125 mmol) was added portionwise over 5 minutes. The solution was warmed r.t. and stirred for 18 h. The reaction mixture was concentrated *in vacuo* and then sat. aq. NaHCO₃ (100 mL) was added. The solution was extracted with CH₂Cl₂ (3 × 75 mL) and then the organic extracts were combined, washed with brine (75 mL), dried over Na₂SO₄ and concentrated *in vacuo* to yield *N*-butylcyclopropylamine (7.20 g, 63%) as a yellow oil, *N.B. Due to volatility issues a cold water bath was used when concentrating in vacuo*; v_{max} / cm⁻¹: 3087 (w), 2957 (s), 2930 (s), 1457 (s), 1214 (s); ¹H NMR (CDCl₃, 400 MHz): δ 2.63 (2H, t, *J* = 7.0 Hz, C**3**-H₂), 2.06 (1H, tt, *J* = 7.0, 4.0 Hz, C**2**-H), 1.55 (1H, br. s, NH), 1.45-1.38 (2H, m, C**4**-H₂), 1.34-1.24 (2H, m, C**5**-H₂), 0.87 (3H, t, *J* = 7.5 Hz, C**6**-H₃), 0.39-0.35 (2H, m, 2 × C**1**-H), 0.29-0.25 (2H, m, 2 × C**1**-H); ¹³C NMR (CDCl₃, 100


MHz): δ 49.4 (C3), 32.3 (C4), 30.4 (C2), 20.6 (C5), 14.0 (C6), 6.3 (C1); HRMS: (ESI⁺) Calculated for C₇H₁₆N: 114.1277. Found [M + H]⁺: 114.1280.

3-Benzyl-1-butyl-1-cyclopropylurea (5f)



General procedure A: *N*-Butylcyclopropanamine (1.25 g, 11.0 mmol) and benzyl isocyanate (1.24 mL, 10.0 mmol) were employed. This crude mixture was purified by column chromatography (40% EtOAc/hexane) to yield the title compound **5f** (1.33 g, 54%) as a colorless solid; m.p. 39-40 °C (CH₂Cl₂/hexane); v_{max} / cm⁻¹: 3327 (m), 1635 (s), 1517 (s), 1372 (m), 1292 (s), 1026 (m); ¹H NMR (CDCl₃, 400 MHz): δ 7.37-7.24 (5H, m, 2 × C**6**-<u>H</u>, 2 × C**7**-<u>H</u>, C**8**-<u>H</u>), 5.52 (1H, t, *J* = 6.0 Hz, N<u>H</u>), 4.47 (2H, d, *J* = 6.0 Hz, C**4**-<u>H</u>₂), 3.35 (2H, t, *J* = 7.0 Hz, C**9**-<u>H</u>₂), 2.46 (1H, tt, *J* = 6.5, 4.0 Hz, C**2**-<u>H</u>), 1.60-1.52 (2H, m, C**10**-<u>H</u>₂), 1.37-1.28 (2H, m, C**11**-<u>H</u>₂), 0.94 (3H, t, *J* = 7.5 Hz, C**12**-<u>H</u>₃), 0.83-0.79 (2H, m, 2 × C**1**-<u>H</u>), 0.73-0.69 (2H, m, 2 × C**1**-<u>H</u>); ¹³C NMR (CDCl₃, 100 MHz): δ 158.8 (C**3**), 139.9 (C**5**), 128.6, 127.4, 127.1 (C**6**, C**7**, C**8**), 46.6 (C**9**), 44.6 (C**4**), 30.5 (C**10**), 27.5 (C**2**), 20.2 (C**11**), 14.0 (C**12**), 8.6 (C**1**); HRMS: (ESI⁺) Calculated for C₁₅H₂₂N₂NaO: 269.1624. Found [M + Na]⁺: 269.1620.


1-Benzyl-3-butyl-3,6-dihydro-1*H*-1,3-diazepine-2,7-dione (8f) *and* 3-Benzyl-1-butyl-1,3-diazepane-2,4-dione (9f)



General Procedure B: Urea **5f** (37.0 mg, 0.150 mmol) and $[Rh(cod)_2]BARF$ (3.5 mol%) were employed and the reaction was stirred for 25 h at 100 °C. The crude mixture was purified by column chromatography (30% EtOAc/hexane) to yield the title compound **8f** (33.3 mg, 82%) as a yellow oil. Analysis of the crude reaction mixture by ¹H NMR revealed a 24:1 (**8f:9f**) mixture of products. The minor product **9f** was not isolated. Data for major compound **8f**: v_{max} / cm^{-1} : 2958 (m), 1699 (s), 1647 (s), 1408 (s), 1212 (s); ¹H NMR (CDCl₃, 400 MHz): δ 7.29-7.20 (5H, m, 2 × C12-<u>H</u>, 2 × C13-<u>H</u>, C14-<u>H</u>), 6.04 (1H, d, *J* = 7.0 Hz, C5-<u>H</u>), 5.56 (1H, dt, *J* = 7.0, 7.0 Hz, C4-<u>H</u>), 5.00 (2H, s, C10-<u>H</u>₂), 3.55 (2H, t, *J* = 7.0 Hz, C6-<u>H</u>₂), 3.09 (2H, d, *J* = 7.0 Hz, C3-<u>H</u>₂), 1.56-1.48 (2H, m, C7-<u>H</u>₂), 1.31-1.22 (2H, m, C8-<u>H</u>₂), 0.90 (3H, t, *J* = 7.0 Hz, C9-<u>H</u>₃); ¹³C NMR (CDCl₃, 100 MHz): δ 170.1 (C2), 153.6 (C1), 137.7 (C11), 130.7 (C5), 128.3, 127.8, 127.1 (C12, C13, C14), 112.4 (C4), 49.9 (C6), 48.0 (C10), 34.9 (C3), 30.2 (C7), 19.9 (C8), 13.7 (C9); HRMS: (ESI⁺) Calculated for C₁₆H₂₀N₂NaO₂: 295.1417. Found [M + Na]⁺: 295.1419.


Data for minor compound **9f**: *Characteristic signals only*: ¹H NMR (CDCl₃, 400 MHz): δ 2.60 (2H, t, J = 7.0 Hz, C**3**-<u>H</u>₂).

3-Benzyl-1-cyclopropyl-1-(naphthalen-1-yl)urea (5g)



General procedure A: *N*-Cyclopropylnaphthalen-1-amine⁴ (1.83 g, 10.0 mmol) and benzyl isocyanate (1.09 mL, 10.0 mmol) were employed. The crude mixture was purified by column chromatography (10-30% EtOAc/hexane) to yield the title compound **5g** (1.15 g, 36%) as a yellow solid; m.p. 109-111 °C (CH₂Cl₂/hexane); v_{max} / cm^{-1} : 3357 (m), 1650 (s), 1504 (s), 1311 (s), 1220 (m); ¹H NMR (CDCl₃, 400 MHz): δ 7.88-7.81 (3H, m, 3 × ArC<u>H</u>), 7.54-7.45 (3H, m, 3 × ArC<u>H</u>), 7.30-7.14 (6H, m, 6 × ArC<u>H</u>), 4.79 (1H, br. s, N<u>H</u>), 4.38 (2H, d, *J* = 6.0 Hz, C4-<u>H</u>₂), 3.26 (1H, tt, *J* = 7.0, 4.0 Hz, C2-<u>H</u>), 0.77-0.69 (2H, m, 2 × C1-<u>H</u>), 0.62-0.47 (2H, m, 2 × C1-<u>H</u>); ¹³C NMR (CDCl₃, 100 MHz): δ 158.5 (C3), 139.6 (C5), 138.0 (C6), 134.8 (ArC), 131.6 (ArC), 128.5, 128.4, 127.4, 127.2, 127.1, 126.7, 126.6, 125.9, 123.1 (10 × ArCH), 44.6 (C4), 31.2 (C2), 7.6 (C1); HRMS: (ESI⁺) Calculated for C₂₁H₂₀N₂NaO: 339.1468. Found [M + Na]⁺: 339.1479.

1-Benzyl-3-(naphthalen-1-yl)-3,6-dihydro-1*H*-1,3-diazepine-2,7-dione (8g) *and* 3-Benzyl-1-(naphthalen-1-yl)-1,3-diazepane-2,4-dione (9g)




General Procedure B: Urea **5g** (47.5 mg, 0.150 mmol) and $[Rh(cod)_2]BARF$ (5.0 mol%) were employed and the reaction was stirred for 72 h at 100 °C. The crude mixture was purified by column chromatography (30% EtOAc/hexane) to yield the title compound **8g** (31.0 mg, 60%) as a yellow oil. Analysis of the crude reaction mixture by ¹H NMR revealed a 16:1 (**8g:9g**) mixture of products. The minor product **9g** was not isolated.

Data for major compound **8g**: v_{max} / cm^{-1} : 2960 (s), 1701 (s), 1652 (s), 1394 (s), 1201 (s), 1141 (m); 1H NMR (CDCl₃, 400 MHz): δ 7.88-7.86 (2H, m, 2 × ArC<u>H</u>), 7.49-7.45 (2H, m, 2 × ArC<u>H</u>), 7.40-7.35 (5H, m, 2 × C**9**-H, 2 × C**10**-<u>H</u>, C**11**-<u>H</u>), 7.28-7.24 (2H, m, 2 × ArC<u>H</u>), 6.93 (1H, d, *J* = 8.5 Hz, 1 × ArC<u>H</u>), 6.11 (1H, dd, *J* = 7.0, 1.0 Hz, C**5**-<u>H</u>), 5.65 (1H, dt, *J* = 7.0, 7.0 Hz, C**4**-<u>H</u>), 5.36 (1H, d, *J* = 14.5 Hz, 1 × C**7**-<u>H</u>), 4.90 (1H, d, *J* = 14.5 Hz, 1 × C**7**-<u>H</u>), 3.50-3.40 (2H, m, C**3**-<u>H</u>₂); ¹³C NMR (CDCl₃, 100 MHz): δ 169.9 (C**2**), 153.6 (C**1**), 137.4 (C**8**), 137.3 (C**6**), 134.6 (Ar<u>C</u>), 131.6 (C**5**), 129.4 128.8, 128.7, 128.5, 128.5, 127.5 (C**9**, C**10**, C**11**, 3 × Ar<u>C</u>), 127.3, 126.5, 126.0, 125.5, 121.8 (5 × Ar<u>C</u>H), 111.1 (C**4**), 48.0 (C**7**), 35.0 (C**3**); HRMS: (ESI⁺) Calculated for C₂₂H₁₈N₂NaO₂: 365.1260. Found [M + Na]⁺: 365.1265.

Data for minor compound **9g**: *Characteristic signals only*: ¹H NMR (CDCl₃, 400 MHz): δ 3.26 (2H, t, J = 7.0 Hz, C**5**-<u>H</u>₂).


tert-Butyl N-(benzylcarbamoyl)-N-cyclopropylglycinate (5h)



To a solution of cyclopropylamine (1.04 mL, 15.0 mmol) and NEt₃ (2.79 mL, 20.0 mmol), in CH₂Cl₂ (20 mL), was added *t*-butyl bromoacetate (1.48 mL, 10.0 mmol) at r.t.. The reaction mixture was stirred for 7 h before cooling to 0 °C. Benzyl isocyanate (1.84 mL, 20.0 mmol) was added and the reaction mixture was warmed to r.t. and stirred for a further 17 h. The resulting solution was diluted with CH₂Cl₂ (25 mL), and washed with water (30 mL), aq. 1 M

HCl (30 mL), sat. aq. NaHCO₃ (30 mL) and brine (30 mL) before being dried over Na₂SO₄ and concentrated *in vacuo*. The crude product was purified by column chromatography (40-50% EtOAc/hexane) to yield the title compound **5h** (1.50 g, 49%) as a colorless solid; m.p. 70-72 °C (CH₂Cl₂/hexane); v_{max} / cm⁻¹: 3359 (s), 2973 (w), 1749 (s), 1639 (s), 1526 (s), 1220 (s), 1151 (s); ¹H NMR (CDCl₃, 400 MHz): δ 7.36-7.31 (4H, m, 2 × C**6**-<u>H</u>, 2 × C**7**-<u>H</u>), 7.26 (1H, m, C**8**-<u>H</u>), 5.67 (1H, br. s, N<u>H</u>), 4.49 (2H, d, *J* = 5.5 Hz, C**4**-<u>H</u>₂), 3.99 (2H, s, C**9**-<u>H</u>₂), 2.71 (1H, m, C**2**-<u>H</u>), 1.47 (9H, s, C**12**-<u>H</u>₃), 0.80 (2H, m, 2 × C**1**-<u>H</u>), 0.73 (2H, m, 2 × C**1**-<u>H</u>); ¹³C NMR (CDCl₃, 100 MHz): δ 170.1 (C**10**), 158.9 (C**3**), 139.7 (C**5**), 128.7 (C**6**), 127.6 (C**7**), 127.3 (C**8**), 81.5 (C**11**), 50.1 (C**9**), 44.8 (C**4**), 28.7 (C**2**), 28.3 (C**12**), 8.8 (C**1**); HRMS: (ESI⁺) Calculated for C₁₇H₂₄N₂NaO₃: 327.1679. Found [M + H]⁺: 327.1684.

tert-Butyl 2-(3-benzyl-2,4-dioxo-2,3,4,5-tetrahydro-1*H*-1,3-diazepin-1-yl)acetate (8h) *and tert*-Butyl 2-(3-benzyl-2,4-dioxo-1,3-diazepan-1-yl)acetate (9h)




General Procedure B: Urea **5h** (45.7 mg, 0.15 mmol) and $[Rh(cod)_2]BARF$ (5.0 mol%) were employed and the reaction was stirred for 48 h at 100 °C. The crude mixture was purified by column chromatography (20% EtOAc/hexane) to yield the title compound **8h** (32.4 mg, 65%) as a colorless oil. Analysis of the crude reaction mixture by ¹H NMR revealed a 23:1 (**8h:9h**) mixture of products. The minor product **9h** was not isolated.

Data for major compound **8h**: m.p. 113-116 °C (CH₂Cl₂/hexane); v_{max} / cm^{-1} : 2976 (w), 1747 (s), 1696 (s), 1647 (s), 1438 (s), 1219 (s), 1152 (s); ¹H NMR (CDCl₃, 400 MHz): δ 7.30-7.19 (5H, m, 2 × C**12**-<u>H</u>, 2 × C**13**-<u>H</u>, C**14**-<u>H</u>), 6.02 (1H, d, *J* = 7.0 Hz, C**5**-<u>H</u>), 5.61 (1H, dt, *J* = 7.0, 7.0 Hz, C**4**-<u>H</u>), 5.00 (2H, s, C**10**-<u>H</u>₂), 4.14 (2H, s, C**6**-<u>H</u>₂), 3.29 (2H, d, *J* = 7.0 Hz, C**3**-<u>H</u>₂), 1.44 (9H, s, C**9**-<u>H</u>₃); ¹³C NMR (CDCl₃, 100 MHz): δ 170.5 (C**2**), 167.3 (C**7**), 154.3 (C**1**), 137.7 (C**11**), 130.9 (C**5**), 128.5, 127.9, 127.3 (C**12**, C**13**, C**14**), 113.7 (C**4**), 82.7 (C**8**), 52.0 (C**6**), 48.2 (C**10**), 35.1 (C**3**), 28.2 (C**9**); HRMS: (ESI⁺) Calculated for C₁₈H₂₂N₂NaO₄: 353.1472. Found [M + Na]⁺: 353.1476.


Data for minor compound **9h**: *Characteristic signals only*: ¹H NMR (CDCl₃, 400 MHz): δ 2.83 (2H, t, J = 7.0 Hz, C**5**-<u>H</u>₂).

3-Benzyl-1-cyclopropyl-1-(cyclopropylmethyl)urea (5i)



(Bromomethyl)cyclopropane (0.97 mL, 10.0 mmol) was added to a stirred solution of cyclopropylamine (2.08 mL, 30.0 mmol) in DMSO (25 mL) at room temperature. The reaction was stirred for 20 h before being diluted with CH_2Cl_2 (200 mL), washed with water (2 × 200 mL) and brine (200 mL). The organics were dried over Na_2SO_4 and carefully concentrated in vacuo. The crude amine was dissolved in CH₂Cl₂ (33 mL) and cooled to 0 °C before adding benzyl isocyanate (1.12 mL, 9.09 mmol). The reaction mixture was warmed to r.t. and stirred for 16 h. The reaction mixture was concentrated in vacuo to yield a crude mixture which was purified by column chromatography (25% EtOAc/hexane) to yield the title compound 5i (1.10 g, 45%) as a colorless solid. m.p. 74-75 °C (CH₂Cl₂/hexane); v_{max} / cm⁻¹: 3375 (s), 2922 (w), 1640 (s), 1628 (s), 1509 (s), 1274 (s); ¹H NMR (CDCl₃, 400 MHz): δ 7.30-7.18 (5H, m, 2 × C6-<u>H</u>, $2 \times C7$ -<u>H</u>, C8-<u>H</u>), 5.54 (1H, br. s, N<u>H</u>), 4.42 (2H, d, J = 6.0 Hz, C4-<u>H</u>₂), 3.18 (2H, d, J= 7.0 Hz, C9-H₂), 2.54 (1H, m, C2-H), 1.00 (1H, m, C10-H), 0.76 (2H, m, C1-H₂), 0.65 (2H, m, C1-H₂), 0.41 (2H, m, C11-H₂), 0.20 (2H, m, C11-H₂); ¹³C NMR (CDCl₃, 100 MHz): δ 159.1 (C3), 140.0 (C5), 128.7 (C7), 127.6 (C6), 127.2 (C8), 51.4 (C9), 44.8 (C4), 27.7 (C2), 10.1 (C10), 9.1 (C1), 3.5 (C11); HRMS: (ESI⁺) Calculated for C₁₅H₂₀N₂NaO: 267.1468. Found [M + Na]⁺: 267.1470.

1-Benzyl-3-(cyclopropylmethyl)-3,6-dihydro-1*H*-1,3-diazepine-2,7-dione (8i) *and* 3-benzyl-1-(cyclopropylmethyl)-1,3-diazepane-2,4-dione (9i)




General Procedure B: Urea **5i** (36.7 mg, 0.15 mmol) and [Rh(cod)₂]BARF (3.5 mol%) were employed and the reaction was stirred for 24 h at 100 °C. The crude mixture was purified by

column chromatography (20% EtOAc/hexane) to yield the title compound **8i** (35.0 mg, 86%) as a brown oil. Analysis of the crude reaction mixture by ¹H NMR revealed a 20:1 (**8i:9i**) mixture of products. The minor product **9i** was not isolated.

Data for major compound **8i**: v_{max} / cm^{-1} : 3003 (w), 1699 (s), 1648 (s), 1409 (s), 1214 (s); ¹H NMR (CDCl₃, 400 MHz): δ 7.31-7.19 (5H, m, 2 × C11-<u>H</u>, 2 × C12-<u>H</u>, C13-<u>H</u>), 6.13 (1H, d, *J* = 7.0 Hz, C5-<u>H</u>), 5.59 (1H, dt, *J* = 7.0, 7.0 Hz, C4-<u>H</u>), 5.01 (2H, s, C9-<u>H</u>₂), 3.46 (2H, d, *J* = 7.0 Hz, C6-<u>H</u>₂), 3.14 (2H, d, *J* = 7.0 Hz, C3-<u>H</u>₂), 1.04 (1H, m, C7-<u>H</u>), 0.49 (2H, m, 2 × C8-<u>H</u>), 0.26 (2H, m, C8-<u>H</u>); ¹³C NMR (CDCl₃, 100 MHz): δ 170.4 (C2), 153.9 (C1), 137.9 (C10), 130.9 (C5), 128.4, 127.9, 127.2 (C11, C12, C13), 112.7 (C4), 54.5 (C6), 48.1 (C9), 35.1 (C3), 10.2 (C7), 3.6 (C8); HRMS: (ESI⁺) Calculated for C₁₆H₁₈N₂NaO₂: 293.1260. Found [M + Na]⁺: 293.1270.


Data for minor compound **9i**: *Characteristic signals only*: ¹H NMR (CDCl₃, 400 MHz): δ 2.65 (2H, t, J = 7.5 Hz, C**3**-<u>H</u>₂).

3-Benzyl-1-cyclopropyl-1-(3,4-dimethoxyphenethyl)urea (5l)



General procedure A: *N*-(3,4-Dimethoxyphenethyl)cyclopropanamine⁵ (664 mg, 3.00 mmol) and benzyl isocyanate (0.370 mL, 3.00 mmol) were employed. The crude mixture was purified by column chromatography (60-80% EtOAc/hexane) to yield the title compound **51** (978 mg, 92%) as a yellow oil; v_{max} / cm^{-1} : 3373 (m), 1644 (s), 1510 (s), 1453 (s), 1259 (s), 1235 (s); ¹H NMR (CDCl₃, 400 MHz): δ 7.34-7.22 (5H, m, 2 × C6-<u>H</u>, 2 × C7-<u>H</u>, C8-<u>H</u>), 6.79-6.75 (3H, m, C12-<u>H</u>, C15-<u>H</u>, C16-<u>H</u>), 5.56 (1H, t, *J* = 5.0 Hz, N<u>H</u>), 4.45 (2H, d, *J* = 5.0 Hz, C4-<u>H</u>₂), 3.84 (3H, s, C17/18-<u>H</u>₃), 3.83 (3H, s, C17/18-<u>H</u>₃), 3.56 (2H, t, *J* = 7.0 Hz, C9-<u>H</u>₂), 2.84 (2H, t, *J* = 7.0 Hz, C10-<u>H</u>₂), 2.32 (1H, tt, *J* = 7.0, 4.0 Hz, C2-<u>H</u>), 0.76-0.72 (2H, m, 2 × C1-<u>H</u>), 0.66-0.58 (2H, m, 2 × C1-<u>H</u>); ¹³C NMR (CDCl₃, 100 MHz): δ 158.7 (C3), 148.8, 147.4 (C14, C15), 139.8 (C5), 132.4 (C11), 128.6, 127.3, 127.1 (C6, C7, C8), 120.8 (C16), 112.2, 111.2 (C12, C15), 55.9, 55.8 (C17, C18), 49.1 (C9), 44.5 (C4), 34.4 (C10), 28.0 (C2), 8.8 (C1); HRMS: (ESI⁺) Calculated for C₂₁H₂₆N₂NaO₃: 377.1836. Found [M + Na]⁺: 377.1833.

1-Benzyl-3-(3,4-dimethoxyphenethyl)-3,6-dihydro-1*H*-1,3-diazepine-2,7-dione (8j) *and* 3-Benzyl-1-(3,4-dimethoxyphenethyl)-1,3-diazepane-2,4-dione (9j)




General Procedure B: Urea **5j** (53.2 mg, 0.150 mmol) and [Rh(cod)₂]OTf (2.5 mol%) were employed and the reaction was stirred for 30 h at 100 °C. The crude mixture was purified by column chromatography (50% EtOAc/hexane) to yield the title compound **8j** (43.9 mg, 77%) as a yellow oil. Analysis of the crude reaction mixture by ¹H NMR revealed a 26:1 (**8j**:**9j**) mixture of products. The minor product **9j** was not isolated.


Data for major compound **8j**: v_{max} / cm^{-1} : 2936 (m), 1699 (s), 1649 (s), 1515 (s), 1410 (s), 1263 (s), 1214 (s), 1028 (s); ¹H NMR (CDCl₃, 400 MHz): δ 7.32-7.21 (5H, m, 2 × C18-<u>H</u>, 2 × C19-<u>H</u>, C20-<u>H</u>), 6.74 (1H, d, *J* = 8.0 Hz, C12-<u>H</u>), 6.69 (1h, d, *J* = 2.0 Hz, C9-<u>H</u>), 6.60 (1H, dd, *J* = 8.0, 2.0 Hz, C13-<u>H</u>), 5.87 (1H, d, *J* = 7.0 Hz, C5-<u>H</u>), 5.46 (dt, *J* = 7.0, 7.0 Hz, C4-<u>H</u>), 5.01 (2H, s, C16-<u>H</u>₂), 3.85-3.78 (8H, m, C6-<u>H</u>₂, C14-<u>H</u>₃, C15-<u>H</u>₃), 2.93 (2H, d, *J* = 7.0 Hz, C3-<u>H</u>₂), 2.82 (2H, t, *J* = 7.0 Hz, C7-<u>H</u>); ¹³C NMR (CDCl₃, 100 MHz): δ 170.1 (C2), 153.6 (C1), 149.0 (C10), 147.8 (C11), 137.7 (C17), 130.8 (C5), 130.4 (C8), 128.4, 127.8, 127.2 (C18, C19, C20), 120.9 (C13), 112.5 (C4), 111.9 (C9), 111.2 (C12), 55.9, 55.9 (C14, C15), 51.5 (C6), 48.0 (C16), 34.8 (C3), 33.9 (C7); HRMS: (ESI⁺) Calculated for C₂₂H₂₄N₂NaO₄: 403.1628. Found [M + Na]⁺: 403.1635.

Data for minor compound **9j**: *Characteristic signals only*: ¹H NMR (CDCl₃, 400 MHz): δ 2.47 (2H, t, J = 7.0 Hz, C**3**-<u>H</u>₂).


4-Benzyl-10,11-dimethoxy-1,7,8,12*b*-tetrahydro-[1,3]diazepino[7,1-*a*]isoquinoline-3,5(2*H*,4*H*)-dione (10j)



A solution of urea 8j (43.1 mg, 0.113 mmol) and TFA (87.0 µL, 1.13 mmol) in CH₂Cl₂ (1 mL) was heated in a sealed tube at 60 °C for 24 h. The reaction mixture was cooled to r.t. and sat. aq. NaHCO₃ (20 mL) was added. The solution was extracted with CH₂Cl₂ (3×15 mL) and the organic extracts were combined, dried over Na₂SO₄ and concentrated in vacuo. The residue was purified by column chromatography (60% EtOAc/hexane) to yield the title compound 10j (39.2 mg, 91%) as a colorless solid; m.p. 176-178 °C (CH₂Cl₂/hexane); v_{max} / cm⁻¹: 1693 (s), 1651 (s), 1519 (s), 1430 (s), 1259 (s), 1230 (s), 1163 (s); ¹H NMR (CDCl₃, 500 MHz): δ 7.39 (2H, dd, J = 7.5, 1.5 Hz, 2 × C18-<u>H</u>), 7.30-7.21 (3H, m, 2 × C19-<u>H</u>, C20-<u>H</u>), 6.67 (1H, s, C9-<u>H</u>), 6.50 (1H, s, C12-<u>H</u>), 4.98 (1H, d, J = 14.5 Hz, $1 \times C16$ -<u>H</u>), 4.86 (1H, d, J = 14.5 Hz, $1 \times C16$ -<u>H</u>), 4.86 (1H, d, J = 14.5 Hz, $1 \times C16$ -<u>H</u>), 4.86 (1H, d, J = 14.5 Hz, $1 \times C16$ -<u>H</u>), 4.86 (1H, d, J = 14.5 Hz, $1 \times C16$ -<u>H</u>), 4.86 (1H, d, J = 14.5 Hz, $1 \times C16$ -<u>H</u>), 4.86 (1H, d, J = 14.5 Hz, $1 \times C16$ -<u>H</u>), 4.86 (1H, d, J = 14.5 Hz, $1 \times C16$ -<u>H</u>), 4.86 (1H, d, J = 14.5 Hz, $1 \times C16$ -<u>H</u>), 4.86 (1H, d, J = 14.5 Hz, $1 \times C16$ -<u>H</u>), 4.86 (1H, d, J = 14.5 Hz, $1 \times C16$ -<u>H</u>), 4.86 (1H, d, J = 14.5 Hz, $1 \times C16$ -<u>H</u>), 4.86 (1H, d, J = 14.5 Hz, $1 \times C16$ -<u>H</u>), 4.86 (1H, d, J = 14.5 Hz, $1 \times C16$ -<u>H</u>), 4.86 (1H, d, J = 14.5 Hz, $1 \times C16$ -<u>H</u>), 4.86 (1H, d, J = 14.5 Hz, $1 \times C16$ -<u>H</u>), 4.86 (1H, d, J = 14.5 Hz, $1 \times C16$ -<u>H</u>), 4.86 (1H, d, J = 14.5 Hz, $1 \times C16$ -<u>H</u>), 4.86 (1H, d, J = 14.5 Hz, $1 \times C16$ -<u>H</u>), 4.86 (1H, d, J = 14.5 Hz, $1 \times C16$ -<u>H</u>), 4.86 (1H, d, J = 14.5 Hz, $1 \times C16$ -<u>H</u>), 4.86 (1H, d, J = 14.5 Hz, $1 \times C16$ -<u>H</u>), 4.86 (1H, d, J = 14.5 Hz, $1 \times C16$ -<u>H</u>), 4.86 (1H, d, J = 14.5 Hz, $1 \times C16$ -<u>H</u>), 4.86 (1H, d, J = 14.5 Hz, $1 \times C16$ -<u>H</u>), 4.86 (1H, d, J = 14.5 Hz, $1 \times C16$ -<u>H</u>), 4.86 (1H, d, J = 14.5 Hz, $1 \times C16$ -<u>H</u>), 4.86 (1H, d, J = 14.5 Hz, $1 \times C16$ -<u>H</u>), 4.86 (1H, d, J = 14.5 Hz, $1 \times C16$ -<u>H</u>), 4.86 (1H, d, J = 14.5 Hz, $1 \times C16$ -<u>H</u>), 4.86 (1H, d, J = 14.5 Hz, $1 \times C16$ -<u>H</u>), 4.86 (1H, d, J = 14.5 Hz, $1 \times C16$ -<u>H</u>), 4.86 (1H, d, J = 14.5 Hz, $1 \times C16$ -<u>H</u>), $1 \times$ C16-<u>H</u>), 4.65 (1H, dd, J = 13.0, 5.5 Hz, C5-<u>H</u>), 3.94 (1H, ddd, J = 12.5, 7.5, 4.5 Hz, $1 \times$ C6-<u>H</u>), 3.87 (3H, s, C14/15-<u>H</u>₃), 3.83 (3H, s, C14/15-<u>H</u>₃), 3.62 (1H, ddd, J = 12.5, 7.5, 4.5 Hz, 1 × C6-H), 2.89-2.73 (3H, m, 1 × C3-H, 2 × C7-H), 2.65 (1H, ddd, *J* = 12.5, 6.5, 1.0 Hz, 1 × C3-H), 2.45 (1H, dddd, J = 13.5, 12.0, 6.5, 5.5 Hz, $1 \times C4$ -H), 2.04 (1H, m, $1 \times C4$ -H); ¹³C NMR (CDCl₃, 125 MHz): δ 171.7 (C2), 157.3 (C1), 148.2, 148.0 (C10, C11), 137.8 (C17) 128.5, 128.5, 127.4 (C18, C19, C20), 126.7 (C13), 126.4 (C8), 111.3 (C9), 109.0 (C12), 50.1, 56.0 (C14, C15), 55.3 (C5), 47.1 (C16), 41.1 (C6), 35.2 (C4), 34.4 (C3), 28.3 (C7); HRMS: (ESI⁺) Calculated for $C_{22}H_{24}N_2NaO_4$: 403.1628. Found $[M + Na]^+$: 403.1615. The structure of this compound was determined unambiguously by X-ray crystallography.




3-Benzyl-1-cyclopropyl-1-(2-(thiophen-3-yl)ethyl)urea (5k)



General procedure A: *N*-(2-(Thiophen-3-yl)ethyl)cyclopropanamine⁵ (418 mg, 2.50 mmol) and benzyl isocyanate (309 µL, 2.50 mmol) were employed. The crude mixture was purified by column chromatography (25% EtOAc/hexane) to yield the title compound **5k** (640 mg, 85%) as a colorless solid; m.p. 77-79 °C (CH₂Cl₂/hexane); v_{max} / cm⁻¹: 3380 (m), 1643 (s), 1504 (s), 1344 (m), 1304 (s); ¹H NMR (CDCl₃, 500 MHz): δ 7.35-7.21 (6H, m, 2 × C6-<u>H</u>, 2 × C7-<u>H</u>, C8-<u>H</u>, C13-<u>H</u>), 7.03-6.97 (2H, m, C12-<u>H</u>, C14-<u>H</u>), 5.52 (1H, br. s, N<u>H</u>), 4.47 (2H, d, *J* = 5.5 Hz, C4-<u>H</u>₂), 3.60 (2H, t, *J* = 7.0 Hz, C9-<u>H</u>₂), 2.93 (2H, t, *J* = 7.0 Hz, C10-<u>H</u>₂), 2.33 (1H, tt, *J* = 6.5, 4.0 Hz, C2-<u>H</u>), 0.81-0.70 (2H, m, 2 × C1-<u>H</u>), 0.67-0.60 (2H, m, 2 × C1-<u>H</u>); ¹³C NMR (CDCl₃, 125 MHz): δ 158.6 (C3), 140.0, 139.8 (C5, C11), 128.6, 128.5, 127.4, 127.1 (C6, C7, C8, C12), 125.3 (C13), 121.1 (C14), 48.1 (C9), 44.6 (C4), 29.2 (C10), 27.9 (C2), 8.7 (C1); HRMS: (ESI⁺) Calculated for C₁₇H₂₀N₂NaOS 323.1189. Found [M + Na]⁺: 323.1190.

1-Benzyl-3-(2-(thiophen-3-yl)ethyl)-3,6-dihydro-1*H*-1,3-diazepine-2,7-dione (8k) *and* 3-Benzyl-1-(2-(thiophen-3-yl)ethyl)-1,3-diazepane-2,4-dione (9k)




General Procedure B: Urea 5k (53.2 mg, 0.150 mmol) and $[Rh(cod)_2]OTf$ (2.5 mol%) were employed and the reaction was stirred for 30 h at 100 °C. The crude mixture was purified by column chromatography (40% EtOAc/hexane) to yield the title compound 8k (45.0 mg, 92%) as a yellow oil. Analysis of the crude reaction mixture by ¹H NMR revealed an 18:1 (8k:9k) mixture of products. The minor product 9k was not isolated.

Data for major compound **8k**: v_{max} / cm^{-1} : 2956 (m), 1698 (s), 1647 (s), 1409 (s), 1265 (s), 1213 (s); ¹H NMR (CDCl₃, 400 MHz): δ 7.32-7.23 (6H, m, C**10**-<u>H</u>, 2 × C**14**-<u>H</u>, 2 × C**15**-<u>H</u>, C**16**-<u>H</u>), 6.87 (1H, dd, J = 5.0, 1.5 Hz, C**9**-<u>H</u>), 6.79 (1H, dd, J = 3.0, 1.5 Hz, C**11**-<u>H</u>), 5.79 (1H, d, J = 7.0 Hz, C**5**-<u>H</u>), 5.45 (1H, dt, J = 7.0, 7.0 Hz, C**4**-<u>H</u>), 5.02 (2H, s, C**12**-<u>H</u>₂), 3.81 (2H, t, J = 7.0 Hz, C**6**-<u>H</u>₂), 2.94-2.89 (4H, m, C**3**-<u>H</u>₂, C**7**-<u>H</u>₂); ¹³C NMR (CDCl₃, 100 MHz): δ 170.1 (C**2**),


153.5 (C1), 138.2 (C8), 137.7 (C13), 130.7 (C5), 128.4, 128.0, 127.9, 127.2 (C9, C14, C15, C16), 126.0 (C10), 121.8 (C11), 112.5 (C4), 50.7 (C6), 47.9 (C12), 34.7 (C3), 28.6 (C7); HRMS: (ESI⁺) Calculated for C₁₈H₁₈N₂NaO₂S: 349.0981. Found [M + Na]⁺: 349.0994.

Data for minor compound **9k**: *Characteristic signals only*: ¹H NMR (CDCl₃, 400 MHz): δ 3.02 (2H, t, *J* = 7.0 Hz, C**5**-<u>H</u>₂).


8-Benzyl-4,10,11,11*a*-tetrahydrothieno[2',3':3,4]pyrido[1,2-*c*][1,3]diazepine- 7,9(5*H*,8*H*)dione (10k)



A solution of **10k** (44.0 mg, 0.135 mmol) and TFA (103 µL, 1.35 mmol) in CH₂Cl₂ (1.5 mL) was heated in a sealed tube at 60 °C for 24 h. The reaction mixture was cooled to r.t. and sat. aq. NaHCO₃ (20 mL) was added. The solution was extracted with CH₂Cl₂ (3×15 mL) and the organic extracts were combined, dried over Na₂SO₄ and concentrated in vacuo. The residue was purified by column chromatography (50% EtOAc/hexane) to yield the title compound 10k (33.4 mg, 76%) as a colorless solid; m.p.: 114-116 °C (CH₂Cl₂/hexane); v_{max} / cm⁻¹: 1695 (s), 1655 (s), 1417 (s), 1336 (s), 1254 (s), 1163 (s); ¹H NMR (CDCl₃, 400 MHz): δ 7.36-7.34 (2H, m, 2 × C14-H), 7.28-7.19 (3H, m, 2 × C15-H, C16-H), 7.16 (1H, d, J = 5.0 Hz, C10-H), 6.78 $(1H, d, J = 5.0 \text{ Hz}, C9-H), 4.94 (1H, d, J = 14.5 \text{ Hz}, 1 \times C12-H), 4.88 (1H, dd, J = 13.0, 5.5)$ Hz, C**5**-H), 4.82 (1H, d, *J* = 14.5 Hz, 1 × C**12**-H), 4.64 (1H, dt, *J* = 13.0, 4.0 Hz, 1 × C**6**-H), 3.12 (1H, m, 1 × C6-H), 2.76-2.60 (4H, m, C3-H₂, 2 × C7-H), 2.45 (1H, m, 1 × C4-H), 2.25 (1H, m, 1 × C4-H); ¹³C NMR (CDCl₃, 100 MHz): δ 171.3 (C2), 157.0 (C1), 137.7 (C13), 134.5 (C8), 133.4 (C11), 128.6, 128.5, 127.5 (C14, C15, C16), 126.9 (C9), 123.8 (C10), 53.6 (C5), 47.3 (C12), 39.3 (C6), 34.0 (C7), 33.9 (C4), 25.5 (C3); HRMS: (ESI⁺) Calculated for $C_{18}H_{18}N_2NaO_2S$: 349.0981. Found [M + Na]⁺: 349.0985. The structure of this compound was determined unambiguously by X-ray crystallography.




1-Benzyl-3-cyclopropylurea (5l)



General procedure A: Cyclopropylamine (0.762 mL, 11.0 mmol) and benzyl isocyanate (1.09 mL, 10.0 mmol) were employed. The crude mixture was purified by recrystallization (CH₂Cl₂/hexane) to yield the title compound **5l** (1.58 g, 83%) as a colorless solid; m.p.: 139-140 °C (CH₂Cl₂/hexane); v_{max} / cm⁻¹: 3309 (s), 1623 (s), 1574 (s), 1453 (m), 1255 (s); ¹H NMR (CDCl₃, 400 MHz): δ 7.37-7.25 (2 × C**6**-<u>H</u>, 2 × C**7**-<u>H</u>, C**8**-<u>H</u>), 5.31 (1H, br. s, N<u>H</u>), 4.79 (1H, br. s, N<u>H</u>), 4.47 (2H, d, *J* = 6.0 Hz, C**4**-<u>H</u>₂), 2.46 (1H, tt, *J* = 7.0, 3.5 Hz, C**2**-<u>H</u>), 0.76-0.71 (2H, m, 2 × C**1**-<u>H</u>), 0.60-0.57 (2H, m, 2 × C**1**-<u>H</u>); ¹³C NMR (CDCl₃, 100 MHz): δ 158.9 (C**3**), 139.4 (C**5**), 128.6, 127.4, 127.3 (C**6**, C**7**, C**8**), 44.2 (C**4**), 22.4 (C**2**), 7.6 (C**1**); HRMS: (ESI⁺) Calculated for C₁₁H₁₄N₂NaO: 213.0998. Found [M + Na]⁺: 213.0997. *The spectroscopic properties of this compound were consistent with the data available in the literature*.⁶

3-Benzyl-1,3-diazepane-2,4-dione (9l) *and* 1-Benzyl-3,6-dihydro-1*H*-1,3-diazepine-2,7-dione (8l)




General Procedure B: Urea **51** (28.5 mg, 0.150 mmol) and [Rh(cod)₂]BARF (5.0 mol%) were employed and the reaction was stirred for 23 h at 90 °C. The crude mixture was purified by column chromatography (30% EtOAc/hexane) to yield the title compound **91** (20.3 mg, 62%, 4:1, **91:81**) as a yellow oil. Analysis of the crude reaction mixture by ¹H NMR revealed a 4:1 (**91:81**) mixture of products.

Data for the mixture of compounds: v_{max} / cm^{-1} : 3300 (m), 2987 (s), 1705 (s), 1537 (s), 1381 (s), 1255 (s).

Data for major compound **91**: ¹H NMR (CDCl₃, 400 MHz): δ 8.79 (1H, br. s, N<u>H</u>), 7.35-7.21 (5H, m, 2 × C**8**-<u>H</u>, 2 × C**9**-<u>H</u>, C**10**-<u>H</u>), 4.50 (2H, d, *J* = 6.0 Hz, C**6**-<u>H</u>₂), 3.89 (2H, t, *J* = 7.0 Hz, C**5**-<u>H</u>₂), 2.61 (2H, t, *J* = 7.0 Hz, C**3**-<u>H</u>₂), 2.04 (2H, tt, *J* = 7.0, 7.0 Hz, C**4**-<u>H</u>₂); ¹³C NMR (CDCl₃, 100 MHz): δ 177.1 (C**2**), 153.0 (C**1**), 138.3 (C**7**), 128.6, 127.4, 127.3 (C**8**, C**9**, C**10**), 45.7 (C**5**), 43.8 (C**6**), 33.4 (C**3**), 17.1 (C**4**); HRMS: (ESI⁺) Calculated for C₁₂H₁₄N₂NaO₂: 241.0947. Found [M + Na]⁺: 241.0963. *The structure of this compound was confirmed by 2D NMR. Key HMBC correlations are included on the compound structure above.*

Data for minor compound **8**I: ¹H NMR (CDCl₃, 400 MHz): δ 8.79 (1H, br. s, N<u>H</u>), 7.35-7.21 (5H, m, 2 × C**8**-<u>H</u>, 2 × C**9**-<u>H</u>, C**10**-<u>H</u>), 6.12 (1H, dd, *J* = 7.0, 4.0 Hz, C**5**-<u>H</u>), 5.44 (1H, dt, *J* = 7.0, 7.0 Hz, C**4**-<u>H</u>), 5.01 (2H, s, C**6**-<u>H</u>₂), 3.20 (2H, d, *J* = 7.0 Hz, C**3**-<u>H</u>₂); ¹³C NMR (CDCl₃, 100 MHz): δ 169.0 (C**2**), 154.2 (C**1**), 137.5 (C**7**), 128.3, 127.9, 127.3 (C**8**, C**9**, C**10**), 126.0 (C**5**), 110.1 (C**4**), 48.0 (C**6**), 35.2 (C**3**); HRMS: (ESI⁺) Calculated for C₁₂H₁₂N₂O₂: 216.0899. Found [M]⁺: 216.0898. *The structure of this compound was confirmed by 2D NMR. Key HMBC correlations are included on the compound structure above.*


1-Butyl-3-cyclopropylurea (5m)



General procedure A: Cyclopropylamine (0.76 mL, 11.0 mmol) and *n*-butyl isocyanate (1.13 mL, 10.0 mmol) were employed. The crude mixture was purified by column chromatography (75% EtOAc/hexane) to yield the title compound **5m** (1.29 g, 83%) as a colorless solid; m.p. 73-74 °C (CH₂Cl₂/hexane); v_{max} / cm⁻¹: 3305 (m), 2931 (m), 1626 (s), 1564 (s), 1250 (m), 1224 (m); ¹H NMR (CDCl₃, 400 MHz): δ 5.00 (1H, br. s, N<u>H</u>), 4.86 (1H, br. s, N<u>H</u>), 3.22 (2H, m, C**4**-<u>H</u>₂), 2.41 (1H, m, C**2**-<u>H</u>), 1.49 (2H, m, C**5**-<u>H</u>₂), 1.35 (2H, m, C**6**-<u>H</u>₂), 0.92 (3H, t, *J* = 7.0

Hz, C7-<u>H</u>₃), 0.73-0.52 (4H, m, C1-<u>H</u>₂); ¹³C NMR (CDCl₃, 100 MHz): δ 159.3 (C3), 40.1 (C4), 32.5 (C5), 22.5 (C2), 20.2 (C6), 13.9 (C7), 7.6 (C1); HRMS: (ESI⁺) Calculated for C₈H₁₆N₂NaO: 179.1155. Found [M + H]⁺: 179.1160.

3-Butyl-1,3-diazepane-2,4-dione (9m) *and* 1-Butyl-3,6-dihydro-1*H*-1,3-diazepine-2,7-dione (8m)




General Procedure B: Urea **5m** (23.4 mg, 0.150 mmol) and [Rh(cod)₂]BARF (5.0 mol%) were employed and the reaction was stirred for 47 h at 90 °C. The crude mixture was purified by column chromatography (40% EtOAc/hexane) to yield the title compound **9m** (19.8 mg, 72%, 5:1, **9m**:**8m**) as a yellow oil. Analysis of the crude reaction mixture by ¹H NMR revealed a 4:1 (**9m**:**8m**) mixture of products.

Data for the mixture of compounds: v_{max} / cm^{-1} : 3307 (w), 2958 (w), 1708 (s), 1541 (s), 1381 (s), 1255 (s).

Data for the major product **9m**: ¹H NMR (CDCl₃, 400 MHz): δ 8.38 (1H, br. s, N<u>H</u>), 3.85 (2H, t, *J* = 7.0 Hz, C**5**-<u>H</u>₂), 3.29 (2H, m, C**6**-<u>H</u>₂), 2.59 (2H, t, *J* = 8.0 Hz, C**3**-<u>H</u>₂), 2.02 (2H, m, C**4**-<u>H</u>₂), 1.52 (2H, m, C**7**-<u>H</u>₂), 1.36 (2H, m, C**8**-<u>H</u>₂), 0.92 (3H, t, *J* = 7.0 Hz, C**9**-<u>H</u>₂); ¹³C NMR (CDCl₃, 100 MHz): δ 177.1 (C**2**), 153.1 (C**1**), 45.8 (C**5**), 39.7 (C**6**), 33.6 (C**3**), 30.5 (C**7**), 20.2 (C**8**), 17.2 (C**4**), 13.9 (C**9**); HRMS: (ESI⁺) Calculated for C₉H₁₆N₂NaO₂: 207.1104. Found [M + Na]⁺: 207.1100.


Data for the minor product **8m**: *Characteristic signals only*: ¹H NMR (CDCl₃, 400 MHz): δ 7.49 (1H, br. s, N<u>H</u>), 6.15 (1H, dd, J = 7.0, 7.0 Hz, C**5**-<u>H</u>), 5.42 (1H, m, C**4**-<u>H</u>), 3.77 (2H, t, J = 7.5 Hz, C**6**-<u>H</u>₂), 3.14 (2H, d, J = 7.0 Hz, C**3**-<u>H</u>₂); ¹³C NMR (CDCl₃, 100 MHz): δ 169.3 (C**2**), 154.9 (C**1**), 126.1 (C**5**), 110.4 (C**4**), 45.3 (C**6**), 35.5 (C**3**), 31.8 (C**7**), 20.2 (C**8**), 13.9 (C**9**).

1-Cyclohexyl-3-cyclopropylurea (5n)



General Procedure A: Cyclopropylamine (0.76 mL, 11.0 mmol) and cyclohexyl isocyanate (1.28 mL, 10.0 mmol) were employed to yield the title compound **5n** (1.67 g, 92%) as a colorless solid; m.p.: 125-126 °C (CH₂Cl₂/hexane); v_{max} / cm^{-1} : 3325 (s), 2926 (w), 1629 (s), 1568 (s), 1253 (w); ¹H NMR (CDCl₃, 400 MHz): δ 4.84 (1H, br. s, N<u>H</u>), 4.60 (1H, br. s, N<u>H</u>), 3.64 (1H, m, C**4**-<u>H</u>), 2.41 (1H, m, C**2**-<u>H</u>), 1.95 (2H, m, C**5**-<u>H</u>₂), 1.74-1.66 (2H, m, C**6**-<u>H</u>₂), 1.64-1.57 (2H, m, C**7**-<u>H</u>₂), 1.43-1.33 (2H, m, C**6**-<u>H</u>₂), 1.23-1.10 (2H, m, C**5**-<u>H</u>₂), 0.73 (2H, m, 2 × C**1**-<u>H</u>), 0.56 (2H, m, 2 × C**1**-<u>H</u>); ¹³C NMR (CDCl₃, 100 MHz): δ 158.5 (C**3**), 48.8 (C**4**), 34.0 (C**5**), 25.8 (C**7**), 25.1 (C**6**), 22.5 (C**2**), 7.7 (C**1**); HRMS: (ESI⁺) Calculated for C₁₀H₁₈N₂NaO: 205.1317. Found [M + Na]⁺: 205.1311.

3-Cyclohexyl-1,3-diazepane-2,4-dione (9n) *and* 1-Cyclohexyl-3,6-dihydro-1*H*-1,3-diazepine-2,7-dione (8n)




General Procedure B: Urea **5n** (27.3 mg, 0.15 mmol) and $[Rh(cod)_2]BARF (5.0 mol%)$ were employed and the reaction was stirred for 51 h at 90 °C. The crude mixture was purified by column chromatography (25% EtOAc/hexane) to yield the title compound **9n** (21.2 mg, 67%) as a pale yellow oil. Analysis of the crude reaction mixture by ¹H NMR revealed a 12:1 (**9n:8n**) mixture of products. The minor product **8n** was not isolated.

Data for the major product **9n**: v_{max} / cm^{-1} : 3291 (br.), 2929 (br.), 2854 (br.), 17.6 (s), 1534 (s), 1380 (m), 1243 (m), 1219 (m); ¹H NMR (CDCl₃, 400 MHz): δ 8.35 (1H, br. m, N<u>H</u>), 3.84 (2H, t, *J* = 7.0 Hz, C**5**-<u>H</u>₂), 3.71 (1H, m, C**6**-<u>H</u>), 2.58 (2H, t, *J* = 8.0 Hz, C**3**-<u>H</u>₂), 2.00 (2H, tt, *J* = 8.0, 7.0 Hz, C**4**-<u>H</u>₂), 1.92-1.88 (2H, m, 2 × C**7**-<u>H</u>), 1.72-1.67 (2H, m, 2 × C**8**-<u>H</u>), 1.60-1.55 (1H, m, 1 × C**9**-<u>H</u>), 1.41-1.31 (2H, m, 2 × C**8**-<u>H</u>), 1.29-1.15 (3H, m, 2 × C**7**-<u>H</u>, 1 × C**9**-<u>H</u>); ¹³C NMR (CDCl₃, 125 MHz): δ 177.1 (C**2**), 152.2 (C**1**), 48.7 (C**6**), 45.8 (C**5**), 33.7 (C**3**), 33.1 (C**7**),

25.7 (C9), 24.8 (C8), 17.1 (C4); HRMS: (ESI⁺) Calculated for $C_{11}H_{18}N_2NaO_2$: 233.1260. Found $[M + Na]^+$: 233.1256.


Data for the minor product **8n**: *Characteristic signals only*: ¹H NMR (CDCl₃, 400 MHz): δ 6.16 (1H, dt, J = 6.0, 2.0 Hz, C4-<u>H</u>).

1-(tert-Butyl)-3-cyclopropylurea (50)



General Procedure A: Cyclopropylamine (0.38 mL, 5.50 mmol) and *tert*-butyl isocyanate (0.43 mL, 5.0 mmol) were employed to yield the title compound **50** (461 mg, 59%) as a colorless solid; v_{max} / cm^{-1} : 3323 (br.), 2965 (m), 1635 (s), 1557 (s), 1453 (m), 1360 (m), 1276 (m), 1218 (s); ¹H NMR (CDCl₃, 400 MHz): δ 4.86 (1H, br. s, N<u>H</u>), 4.54 (1H, br. s, N<u>H</u>), 2.38 (1H, m, C2-<u>H</u>), 1.35 (9H, s, C5-<u>H</u>₃), 0.70 (2H, m, 2 × C1-<u>H</u>), 0.53 (2H, m, 2 × C1-<u>H</u>); ¹³C NMR (CDCl₃, 100 MHz): δ 158.4 (C3), 50.5 (C4), 29.6 (C5), 22.7 (C2), 7.6 (C1); HRMS: (ESI+) Calculated for C₈H₁₆N₂NaO: 179.1155. Found [M + Na]⁺: 179.1155.

3-(*tert*-Butyl)-1,3-diazepane-2,4-dione (90) *and* 1-(*tert*-Butyl)-3,6-dihydro-1*H*-1,3-diazepine-2,7-dione (80)




General Procedure B: Urea **50** (23.4 mg, 0.15 mmol) and [Rh(cod)₂]BARF (5.0 mol%) were employed and the reaction was stirred for 48 h at 90 °C. The crude mixture was purified by column chromatography (50% EtOAc/hexane) to yield the title compound **90** (21.2 mg, 53%, 5:1, **90:80**) as a pale yellow oil. Analysis of the crude reaction mixture by ¹H NMR revealed a 4:1 (**90:80**) mixture of products.

Data for the mixture of compounds: v_{max} / cm^{-1} :3288 (br.), 2966 (br.), 1710 (s), 1547 (s), 1383 (m), 1364 (m), 1263 9m), 1201 (m).

Data for the major product **90**: ¹H NMR (CDCl₃, 400 MHz): δ 8.41 (1H, br. s, N<u>H</u>), 3.82 (2H, t, *J* = 7.0 Hz, C**5**-<u>H</u>₂), 2.58 (2H, t, *J* = 8.0 Hz, C**3**-<u>H</u>₂), 1.99 (2H, tt, *J* = 8.0, 7.0 Hz, C**4**-<u>H</u>₂), 1.37 (9H, s, C**7**-<u>H</u>₃); ¹³C NMR (CDCl₃, 100 MHz): δ 177.0 (C**2**), 151.6 (C**1**), 50.9 (C**6**), 45.6 (C**6**), 33.8 (C**3**), 29.0 (C**7**), 17.0 (C**4**); HRMS: (ESI⁺) Calculated for C₉H₁₆N₂NaO₂: 207.1104. Found [M + Na]⁺: 207.1114.


Data for the minor product **80**: *Characteristic signals only*: ¹H NMR (CDCl₃, 400 MHz): δ ; ¹³C NMR (CDCl₃, 100 MHz): δ ; 8.34 (1H, br. s, N<u>H</u>), 6.18 (1H, dt, J = 6.0, 2.0 Hz, C**5**-<u>H</u>), 4.42 (1H, t, J = 2.0 Hz, C**4**-<u>H</u>), 1.40 (9H, s, C**7**-<u>H</u>₃); ¹³C NMR (CDCl₃, 100 MHz): δ 146.1 (C**5**), 51.0 (C**3**), 29.1 (C**7**).

1-Cyclopropyl-3-phenylurea (5p)



General procedure A: Cyclopropylamine (0.76 mL, 11.0 mmol) and phenyl isocyanate (0.90 mL, 10.0 mmol) were employed to yield the title compound **5p** (1.30 g, 74%) as a colorless solid; m.p. 160-161 °C (CH₂Cl₂/hexane); v_{max} / cm⁻¹: 3341 (w), 1642 (s), 1594 (s), 1547 (s), 1242 (s), 741 (s); ¹H NMR (CDCl₃, 400 MHz): δ 7.38 (2H, m, 2 × C**5**-<u>H</u>), 7.29 (2H, m, 2 × C**6**-<u>H</u>), 7.07 (1H, br. s, N<u>H</u>), 7.05 (1H, m, C**7**-<u>H</u>), 5.17 (1H, br. s, N<u>H</u>), 2.59 (1H, m, C**2**-<u>H</u>), 0.81 (2H, m, 2 × C**1**-<u>H</u>), 0.62 (2H, m, 2 × C**1**-<u>H</u>); ¹³C NMR (CDCl₃, 100 MHz): δ 156.8 (C**3**), 138.7 (C**4**), 129.2 (C**6**), 123.5 (C**7**), 120.2 (C**5**), 22.7 (C**2**), 7.6 (C**1**); HRMS: (ESI⁺) Calculated for C₁₀H₁₂N₂NaO: 199.0842. Found [M + Na]⁺: 199.0847.

3-Phenyl-1,3-diazepane-2,4-dione (9p) *and* 1-Phenyl-3,6-dihydro-1*H*-1,3-diazepine-2,7-dione (8p)




General Procedure B: Urea **5p** (26.4 mg, 0.15 mmol) and [Rh(cod)₂]BARF (5.0 mol%) were employed with 1,4-dioxane as solvent and the reaction was stirred for 49 h at 90 °C. The crude

mixture was purified by column chromatography (25% EtOAc/hexane) to yield the title compound **9p** (20.5 mg, 67%, 25:1, **9p:8p**) as a beige solid. Analysis of the crude reaction mixture by ¹H NMR revealed a 12:1 (**9p:8p**) mixture of products. The minor product **8p** was not isolated.

Data for the major product **9p**: m.p. 89-92 °C (CH₂Cl₂/hexane); v_{max} / cm^{-1} : 3088 (m), 1719 (s), 1599 (s), 1556 (s), 1379 (s), 1210 (s); ¹H NMR (CDCl₃, 400 MHz): δ 10.54 (1H, br. s, N<u>H</u>), 7.53 (2H, m, 2 × C**8**-<u>H</u>), 7.33 (2H, m, 2 × C**7**-<u>H</u>), 7.10 (1H, t, C**9**-<u>H</u>), 3.95 (2H, t, *J* = 7.2 Hz, C**5**-<u>H</u>₂), 2.69 (2H, t, *J* = 8.0 Hz, C**3**-<u>H</u>₂), 2.09 (2H, dt, *J* = 8.0, 7.0 Hz, C**4**-<u>H</u>₂); ¹³C (CDCl₃, 100 MHz): δ 177.3 (C**2**), 150.1 (C**1**), 137.4 (C**7**), 129.0 (C**8**), 124.0 (C**10**), 120.0 (C**9**), 45.7, 33.5 (C**3**, C**5**), 16.8 (C**4**). HRMS: (ESI⁺) Calculated for C₁₁H₁₂N₂NaO₂: 227.0791. Found [M + Na]⁺: 227.0791.


Data for the minor product **8p**: *Characteristic signals only*: ¹H NMR (CDCl₃, 400 MHz): δ 6.25 (1H, dt, J = 6.0, 2.0 Hz, C**4**-<u>H</u>).

1-Cyclopropyl-3-(4-(trifluoromethyl)phenyl)urea (5q)



General procedure A: Cyclopropylamine (0.38 mL, 5.50 mmol) and 4-(trifluoromethyl)phenyl isocyanate (0.71 mL, 5.00 mmol) were employed to yield the title compound **5q** (1.00 g, 82%) as a colorless solid; m.p. 180-181 °C (CHCl₃); v_{max} / cm⁻¹: 3313 (br.), 1651 (s), 1603 (m), 1544 (s), 1326 (s), 1161 (s), 1107 (s), 1062 (s); ¹H NMR (MeOD-d4, 400 MHz): δ 7.58-7.51 (4H, m, 2 × C**5**-<u>H</u>, 2 × C**6**-<u>H</u>), 2.60 (1H, m, C**2**-<u>H</u>), 0.75 (2H, m, 2 × C**1**-<u>H</u>), 0.51 (2H, m, 2 × C**1**-<u>H</u>); ¹³C NMR (CDCl₃, 100 MHz): δ 158.9 (C**3**), 144.6 (C**8**), 127.0, 119.4 (C**5**, C**6**), 23.3 (C**2**), 7.3 (C**1**); HRMS: (ESI⁺) Calculated for C₁₁H₁₁F₃N₂NaO: 267.0716. Found [M + Na]⁺: 267.0714.

3-(4-(Trifluoromethyl)phenyl)-1,3-diazepane-2,4-dione (9q) *and* 1-(4-(Trifluoromethyl) phenyl)-3,6-dihydro-1*H*-1,3-diazepine-2,7-dione (8q)




General Procedure B: Urea **5q** (36.6 mg, 0.15 mmol) and $[Rh(cod)_2]BARF$ (5.0 mol%) were employed and the reaction was stirred for 42 h at 90 °C. The crude mixture was purified by column chromatography (30% EtOAc/hexane) to yield the title compound **9q** (29.1 mg, 71%, 3:1, **9q:8q**) as a yellow solid. Analysis of the crude reaction mixture by ¹H NMR revealed a 3:1 (**9q:8q**) mixture of products.

Data for the mixture of compounds: v_{max} / cm^{-1} : 3131 (br.), 3075 (br.), 1707 (s), 1692 (s), 1602 (m), 1557 (m), 1325 (m), 1112 (s).

Data for major compound **9q**: ¹H NMR (CDCl₃, 400 MHz): δ 10.80 (1H, br. s, N<u>H</u>), 7.72-7.54 (4H, m, 2 × C**7**-<u>H</u>, 2 × C**8**-<u>H</u>), 3.96 (2H, t, *J* = 7.0 Hz, C**5**-<u>H</u>₂), 2.71 (2H, t, *J* = 8.0 Hz, C**3**-<u>H</u>₂), 2.11 (2H, tt, *J* = 8.0, 7.0 Hz, C**4**-<u>H</u>₂); ¹³C NMR (CDCl₃, 125 MHz): δ 177.7 (C**2**), 126.4, 119.7 (C**7**, C**8**), 45.8 (C**5**), 33.6 (C**3**), 16.9 (C**4**); HRMS: (ESI⁺) Calculated for C₁₂H₁₁F₃N₂NaO₂: 295.0665. Found [M + Na]⁺: 295.0659.


Data for minor compound **8q**: ¹H NMR (CDCl₃, 400 MHz): δ 10.70 (1H, br. s, N<u>H</u>), 7.72 -7.54 (4H, m, 2 × C**7**-<u>H</u>, 2 × C**8**-<u>H</u>), 7.40 (1H, dt, *J* = 6.0, 2.0 Hz, C**5**-<u>H</u>), 6.29 (1H, dt, *J* = 6.0, 2.0 Hz, C**4**-<u>H</u>), 4.56 (2H, dd, *J* = 2.0, 2.0 Hz, C**3**-<u>H</u>₂); ¹³C NMR (CDCl₃, 125 MHz): δ 172.0 (C**2**), 147.3 (C**5**), 127.2 (C**4**), 126.4, 119.7 (C**7**, C**8**), 51.4 (C**3**).

1-Cyclopropyl-3-(4-methoxyphenyl)urea (5q)



General procedure A: Cyclopropylamine (0.76 mL, 11.0 mmol) and 1-isocyanato-4methoxybenzene (1.09 mL, 10.0 mmol) were employed to yield the title compound **5q** (1.98 g, 96%) as a colorless solid; m.p. 146-149 °C (CH₂Cl₂); v_{max} / cm⁻¹: 3289 (m), 1637 (s), 1561 (s), 1508 (s), 1243 (s); ¹H NMR (CDCl₃, 400 MHz): δ 7.28 (2H, m, 2 × C6-<u>H</u>), 6.86 (2H, m, 2 × C5-<u>H</u>), 6.68 (1H, br. s, N<u>H</u>), 3.79 (3H, s, C8-<u>H</u>₃), 2.58 (1H, m, C2-<u>H</u>), 0.81 (2H, m, 2 × C1<u>H</u>), 0.63 (2H, m, $2 \times C1$ -<u>H</u>); ¹³C NMR (CDCl₃, 100 MHz): δ 156.5 (C7), 131.3 (C4), 123.3 (C6), 114.5 (C5), 55.6 (C8), 22.8 (C2), 7.78 (C1); HRMS: (ESI⁺) Calculated for C₁₁H₁₄N₂NaO: 229.0953. Found [M + Na]⁺: 229.0947.

3-(4-Methoxyphenyl)-1,3-diazepane-2,4-dione (9r) *and* 1-(4-Methoxyphenyl)-3,6dihydro-1*H*-1,3-diazepine-2,7-dione (8r)




General Procedure B: Urea **5r** (30.9 mg, 0.15 mmol) and $[Rh(cod)_2]BARF$ (5.0 mol%) were employed and the reaction was stirred for 25 h at 90 °C. The crude mixture was purified by column chromatography (30% EtOAc/hexane) to yield the title compound **9r** (22.0 mg, 63%) as a colorless solid. Analysis of the crude reaction mixture by ¹H NMR revealed a 12:1 (**9r:8r**) mixture of products. The minor product **8r** was not isolated.


Data for major compound **9r**: m.p. 114-116 °C (CH₂Cl₂/hexane); v_{max} / cm^{-1} : 2918 (m), 1702 (s), 1552 (s), 1511 (s), 1382 (s), 1212 (s); ¹H NMR (CDCl₃, 400 MHz): δ 10.4 (1H, br. s, N<u>H</u>), 7.42 (2H, m, 2 × C**8**-<u>H</u>), 6.86 (2H, m, 2 × C**7**-<u>H</u>), 3.94 (2H, t, *J* = 7.0 Hz, C**5**-<u>H</u>₂), 3.78 (3H, s, C**10**-<u>H</u>₃), 2.68 (2H, t, *J* = 8.0 Hz, C**3**-<u>H</u>₂), 2.07 (2H, tt, *J* = 8.0, 7.0 Hz, C**4**-<u>H</u>₂); ¹³C NMR (CDCl₃, 100 MHz): δ 177.3 (C**2**), 156.4 (C**9**), 150.5 (C**1**), 130.6 (C**6**), 121.9 (C**8**), 114.3 (C**7**), 55.6 (C**10**), 45.8 (C**5**), 33.7 (C**3**), 16.9 (C**4**); HRMS: (ESI⁺) Calculated for C₁₂H₁₄N₂NaO₃: 257.0902. Found [M + Na]⁺: 257.08967.

Data for the minor product **8r**: *Characteristic signals only*: ¹H NMR (CDCl₃, 400 MHz): δ 6.25 (1H, d, J = 6.0 Hz, C**4**-<u>H</u>).


1,3-Dibenzyl-1-((1S*,2S*)-2-methylcyclopropyl)urea (*trans*-5s)



General procedure A: (1*S**,2*S**)-*N*-Benzyl-2-methylcyclopropan-1-amine⁵ (968 mg, 6.00 mmol) and benzyl isocyanate (0.74 μL, 6.00 mmol) were employed. The crude mixture was purified by column chromatography (30% EtOAc/hexane) to yield the title compound *trans*-**5**s (1.58 g, 89%) as a colorless oil; m.p. 49-51 °C (CH₂Cl₂/hexane); v_{max} / cm⁻¹: 3363 (m), 2957 (m), 1631 (s), 1504 (s), 1454 (s), 1221 (s); ¹H NMR (CDCl₃, 400 MHz): δ 7.36-7.22 (10H, m, $2 \times$ C**8**-<u>H</u>, $2 \times$ C**9**-<u>H</u>, C**10**-<u>H</u>, $2 \times$ C**13**-<u>H</u>, $2 \times$ C**14**-<u>H</u>, C**15**-<u>H</u>), 5.48 (1H, t, *J* = 5.5 Hz, N<u>H</u>), 4.62-4.49 (4H, m, C**6**-<u>H</u>₂, C**11**-<u>H</u>₂), 2.02 (1H, ddd, *J* = 7.0, 7.0, 3.5 Hz, C**4**-<u>H</u>), 1.11 (1H, m, C**2**-<u>H</u>), 0.97 (3H, d, *J* = 6.0 Hz, C**1**-<u>H</u>₃), 0.91 (1H, m, $1 \times$ C**3**-<u>H</u>), 0.55 (1H, m, $1 \times$ C**3**-<u>H</u>); ¹³C NMR (CDCl₃, 100 MHz): δ 159.0 (C**5**), 139.8, 139.0 (C**7**, C**12**), 128.7, 128.5, 128.1, 127.5, 127.3, 127.1 (C**8**, C**9**, C**10**, C**13**, C**14**, C**15**), 50.3 (C**11**), 45.0 (C**6**), 35.3 (C**4**), 16.9 (C**1**), 16.8 (C**3**), 16.6 (C**2**); HRMS: (ESI⁺) Calculated for C₁₉H₂₂N₂NaO: 317.1624. Found [M + Na]⁺: 317.1632. *The structure and relative stereochemistry of this compound was determined unambiguously by X-ray crystallography.*




1,3-Dibenzyl-1-((1*S*,2*S*)-2-methylcyclopropyl)urea ((*S*,*S*)-*trans*-5s)



Enantiopure substrate (S,S)-*trans*-5s (99% e.e.)was synthesised starting from commercially available (*R*)-propylene oxide according to the literature procedure.^{5,7}


$$[\alpha]_{\mathbf{D}}^{\mathbf{27}}$$
 +41.1 (c = 1.2, CHCl₃).

The enantiopurity of this compound was determined by chiral SFC (Chiralpak IB, isocratic CO₂-MeOH 88:12, 2.0 mL/min, 40 °C) against a racemic standard; t_R (major) – 4.8 min and t_R (minor) – 5.0 min.




Peak	RetTime	Туре	Width	Area	Height	Area
#	[min]		[min]	[mAU*s]	[mAU]	%
1	4.736	BV	0.0902	1.43725e4	1889.92505	48.4774
2	4.956	VB	0.0965	1.52754e4	1885.69458	51.5226

1,3-Dibenzyl-6-methyl-3,6-dihydro-1*H*-1,3-diazepine-2,7-dione (8s)



General Procedure B: Urea *trans-5s* (44.2 mg, 0.15 mmol) and [Rh(cod)₂]BARF (7.5 mol%) were employed and the reaction was stirred for 73 h at 100 °C. The crude mixture was purified by column chromatography (10% EtOAc/hexane) to yield the title compound **8s** (33.5 mg, 70%) as a yellow oil. Analysis of the crude reaction mixture by ¹H NMR revealed complete selectivity for **8s** over the corresponding saturated product **9s** and C4-substituted regioisomer **8s'**; v_{max} / cm^{-1} : 2987 (m), 1699 (s), 1649 (s), 1402 (s), 1265 (s), 1183 (s), 1076 (s), 1046 (s); ¹H NMR (CDCl₃, 400 MHz): δ 7.31-7.22 (8H, m, 2 × C**9**-<u>H</u>, C**10**-<u>H</u>, 2 × C**13**-<u>H</u>, 2 × C**14**-<u>H</u>, C**15**-<u>H</u>), 7.07-7.02 (2H, m, 2 × C**8**-<u>H</u>), 5.99 (1H, dd, *J* = 7.0 Hz, 2.0 Hz, C**5**-<u>H</u>), 5.27 (1H, d, *J* = 14.5 Hz, 1 × C**11**-<u>H</u>), 5.21 (1H, dd, *J* = 7.0, 6.0 Hz, C**4**-<u>H</u>), 4.90 (1H, d, *J* = 14.5 Hz, 1 × C**11**-<u>H</u>), 4.83 (1H, d, *J* = 15.0 Hz, 1 × C**6**-<u>H</u>), 4.66 (1H, d, *J* = 15.0 Hz, 1 × C**6**-<u>H</u>), 3.06 (1H, qdd, *J* = 7.0, 6.0, 2.0 Hz, C**3**-<u>H</u>), 1.35 (3H, d, *J* = 7.0 Hz, C**16**-<u>H</u>₃); ¹³C NMR (CDCl₃, 100 MHz): δ 172.3 (C**2**), 154.0 (C**1**), 137.7 (C**12**), 136.1 (C**7**), 128.7, 128.5, 128.4, 128.1, 127.7, 127.6, 127.2 (C**5**, C**8**, C**9**, C**10**, C**13**, C**14**, C**15**), 120.2 (C**4**), 52.9 (C**6**), 48.2 (C**11**), 38.0 (C**3**), 13.7 (C**16**); HRMS: (ESI⁺) Calculated for C₂₀H₂₀N₂NaO₂: 343.1417. Found [M + Na]⁺: 343.1413.


(S)-1,3-Dibenzyl-6-methyl-3,6-dihydro-1*H*-1,3-diazepine-2,7-dione ((S)-8s)



General Procedure B: Urea (*S*,*S*)-*trans*-5s (44.2 mg, 0.15 mmol) and $[Rh(cod)_2]BARF$ (7.5 mol%) were employed and the reaction was stirred for 74 h at 100 °C. The crude mixture was purified by column chromatography (10% EtOAc/hexane) to yield the title compound (*S*)-8s (21.1 mg, 65%, 99% e.e.) as a yellow oil.


 $[\alpha]_{D}^{27}$ +205.2 (c = 1.2, CHCl₃).

The enantiopurity of this compound was determined by chiral SFC (Chiralpak IB, isocratic CO₂-MeOH 95:5, 1.0 mL/min, 8 °C) against a racemic standard; t_R (major – 16.4 min and t_R (minor) – 17.2 min.




Peak	RetTime	Туре	Width	Area	Height	Area
#	[min]		[min]	[mAU*s]	[mAU]	010
1	16.457	MF	0.2961	5930.83105	333.84116	49.7717
2	17.100	FM	0.3346	5985.22900	298.11276	50.2283

1,3-Dibenzyl-1-((1*R**,2*R**)-2-butylcyclopropyl)urea (*trans*-5t)




General procedure A: $(1R^*, 2R^*)$ -*N*-Benzyl-2-butylcyclopropan-1-amine⁵ (497 mg, 2.44 mmol) was employed and the residue was purified by column chromatography (20% EtOAc/hexane) to provide the title compound *trans*-5t (677 mg, 82%) as a colorless oil; v_{max} / cm^{-1} : 2956 (m), 2923 (m), 1644 (s), 1513 (s), 1453 (m), 1352 (m), 1267 (m); ¹H NMR (CDCl₃, 400 MHz): δ 7.37-7.21 (10H, m, 2 x C11-<u>H</u>, 2 x C12-<u>H</u>, C13-<u>H</u>, 2 x C16-<u>H</u>, 2 x C17-<u>H</u>, C18-<u>H</u>), 5.52 (1H, m, N<u>H</u>), 4.57 (2H, s, C14-<u>H</u>), 4.50 (2H, t, *J* = 5.0 Hz, C9-<u>H</u>), 2.08 (1H, m, C7-<u>H</u>), 1.26-1.17 (5H, m, 2 x C2-<u>H</u>, 2 x C3-<u>H</u>, 1 × C4-<u>H</u>), 1.12-1.01 (2H, m, 1 × C4-<u>H</u>, 1 × C5-<u>H</u>), 0.87 (1H, m, 1 × C6-<u>H</u>), 0.81 (3H, m, C1-<u>H</u>₃), 0.55 (1H, m, 1 × C6-<u>H</u>); ¹³C NMR (CDCl₃, 100 MHz): δ 159.0 (C8), 139.8 (C10), 139.2 (C15), 128.8, 128.5, 127.9, 127.7, 127.4, 127.0 (C11, C12, C13, C16, C17, C18), 50.5 (C14), 45.0 (C9), 34.5 (C7), 32.1 (C4), 31.1, 22.6 (C2, C3), 22.4 (C5), 15.8 (C6), 14.0 (C1); HRMS: (ESI⁺) Calculated for C₂₂H₂₈N₂NaO: 359.2094. Found [M + Na]⁺: 359.2094. *The relative stereochemistry of this compound was corroborated by nOe experiments (as indicated on the compound structure). A strong nOe was observed between C7-<u>H</u> and C4-<u>H</u>₂. No significant nOe was observed between C7-<u>H</u> and C5-<u>H</u>.*

1,3-Dibenzyl-6-butyl-3,6-dihydro-1*H*-1,3-diazepine-2,7-dione (8t)



General Procedure B: Urea *trans*-5t (50.5 mg, 0.15 mmol) and [Rh(cod)₂]BF₄ (10 mol%) were employed and the reaction was stirred for 45 h at 100 °C. The crude mixture was purified by column chromatography (7.5% EtOAc/hexane) to yield the title compound **8t** (32.2 mg, 59%) as a yellow solid. Analysis of the crude reaction mixture by ¹H NMR revealed complete selectivity for **8t** over the corresponding saturated product **9t** and C4-substituted regioisomer **8t**'; m.p. 88-89 °C (CH₂Cl₂/hexane); v_{max} / cm⁻¹: 2954 (m), 1688 (s), 1646 (s), 1446 (m), 1405 (s), 1332 (m), 1272 (m), 1181 (m); ¹H NMR (CDCl₃, 400 MHz): δ 7.31-7.21 (8H, m, 2 × C**9**-H, C**10**-H, 2 × C**13**-H, 2 × C**14**-H, C**15**-H), 7.06-7.03 (2H, m, 2 × C**8**-H), 6.01 (1H, dd, *J* = 7.0, 2.0 Hz, C**5**-H), 5.26-5.23 (2H, m, C**4**-H, 1 × C**11**-H), 4.90 (1H, d, *J* = 14.5 Hz, 1 × C**11**-H), 4.81 (1H, d, *J* = 15.0 Hz, 1 × C**6**-H), 4.68 (1H, d, *J* = 15.0 Hz, 1 × C**6**-H), 2.89 (1H, m, C**3**-H), 1.96 (1H, m, 1 × C**16**-H), 1.64 (1H, m, 1 × C**16**-H), 1.33-1.25 (4H, m, 2 × C**17**-H, 2 × C**18**-H), 0.89 (3H, m, C**19**-H₃); ¹³C NMR (CDCl₃, 125 MHz): δ 171.8 (C**2**), 154.2 (C**1**), 137.9 (C**12**), 136.3 (C**7**), 129.0, 128.8, 128.5, 128.2, 127.9, 127.7, 127.3 (C**5**, C**8**, C**9**, C**10**, C**13**, C**14**, C**15**, 119.7 (C**4**), 22.9 (C**6**), 48.2 (C**11**), 43.7 (C**3**), 29.3 (C**17**), 27.9 (C**16**), 22.5 (C**18**), 14.1 (C**9**); HRMS: (ESI⁺) Calculated for C₂₃H₂₆N₂NaO₂: 385.1886. Found [M + Na]⁺: 385.1891.


1,3-Dibenzyl-1-((1*R**,2*S**)-2-cyclohexylcyclopropyl)urea (*trans*-5u)



General procedure A: $(1R^*, 2S^*)$ -*N*-Benzyl-2-cyclohexylcyclopropan-1-amine⁵ (355 mg, 1.55 mmol) was employed and the residue was purified by column chromatography (15-20%)

EtOAc/hexane) to provide the title compound *trans*-5u (500 mg, 89%) as a colorless oil; m.p. 73-74 °C (CH₂Cl₂/hexane); v_{max} / cm⁻¹: 3346 (m), 2922 (m), 1630 (s), 1518 (s), 1349 (m), 1221 (m), 696 (s); ¹H NMR (CDCl₃, 400 MHz): δ 7.37-7.21 (10H, m, 2 × C11-<u>H</u>, 2 × C12-<u>H</u>, C13-<u>H</u>, 2 × C16-<u>H</u>, 2 × C17-<u>H</u>, C18-<u>H</u>,), 5.63 (1H, t, *J* = 5.0 Hz, N<u>H</u>), 4.64 (1H, d, *J* = 15.5 Hz, 1 × C14-<u>H</u>), 4.51 (1H, d, *J* = 15.5 Hz, 1 × C14-<u>H</u>), 4.49 (2H, m, C9-<u>H</u>₂), 2.20 (1H, m, C7-<u>H</u>), 1.68-1.50 (5H, m, 5 × cyclohexyl C<u>H</u>), 1.13-0.88 (6H, m, C4-<u>H</u>, 5 × cyclohexyl C<u>H</u>), 0.82 (1H, m, 1 × C6-<u>H</u>), 0.64-0.47 (2H, m, C5-<u>H</u>, 1 × C6-<u>H</u>); ¹³C NMR (CDCl₃, 100 MHz): δ 159.0 (C8), 139.7 (C10), 139.4 (C15), 128.7, 128.5, 127.9, 127.7, 127.4, 126.9 (C11, C12, C13, C16, C17, C18), 50.7 (C14), 45.1 (C9), 41.0 (C5), 33.7 (C7), 32.7, 32.1 (2 × cyclohexyl <u>C</u>H₂), 28.7 (C4), 26.3, 26.1, 26.1 (3 × cyclohexyl <u>C</u>H₂), 14.7 (C6); HRMS: (ESI⁺) Calculated for C₂₄H₃₀N₂NaO: 385.2256. Found [M + Na]⁺: 385.2342.






General Procedure B: Urea *trans*-5u (54.4 mg, 0.15 mmol) and $[Rh(cod)_2]BF_4$ (7.5 mol%) were employed and the reaction was stirred for 73 h at 100 °C. The crude mixture was purified by column chromatography (7.5% EtOAc/hexane) to yield the title compound 8u (16.9 mg, 29%) as a yellow oil. Analysis of the crude reaction mixture by ¹H NMR revealed complete selectivity for 8u over the corresponding saturated product 9u and C4-substituted regioisomer 8u'; v_{max} / cm⁻¹: 2923 (m), 2850 (m), 1698 (m), 1646 (s), 1401 (s), 1178 (m); ¹H NMR (CDCl₃, 400 MHz): δ 7.30-7.21 (8H, m, 2 × C9-<u>H</u>, C10-<u>H</u>, 2 × C13-<u>H</u>, 2 × C14-<u>H</u>, C15-<u>H</u>), 7.07-7.03 (2H, m, 2 × C8-<u>H</u>), 6.01 (1H, dd, *J* = 7.0, 1.5 Hz, C5-<u>H</u>), 5.38 (1H, dd, *J* = 7.0, 7.0 Hz, C4-<u>H</u>), 5.18 (1H, d, *J* = 14.5 Hz, 1 × C11-<u>H</u>), 4.92 (1H, d, *J* = 14.5 Hz, 1 × C11-<u>H</u>), 4.84 (1H, d, *J* = 15.0 Hz, 1 × C6-<u>H</u>), 2.67 (1H, m, C3-<u>H</u>), 1.96-1.86 (2H, m, C16-<u>H</u>, 1 × C17-<u>H</u>), 1.79 (1H, m, 1 × cyclohexyl C<u>H</u>), 1.70-1.63 (3H, m, 3 × cyclohexyl


C<u>H</u>), 1.34-1.08 (3H, m, 3 × cyclohexyl C<u>H</u>), 0.91-0.79 (2H, m, 1 × C**17**-<u>H</u>, 1 × cyclohexyl C<u>H</u>); ¹³C NMR (CDCl₃, 125 MHz): δ 170.7 (C**2**), 154.2 (C**1**), 137.9 (C**12**), 136.2 (C**7**), 129.1 (C**5**), 128.8, 128.5, 128.2, 127.9, 127.8, 127.3 (C**8**, C**9**, C**10**, C**13**, C**14**, C**15**), 117.8 (C**4**), 52.9 (C**6**), 50.2 (C**3**), 48.3 (C**11**), 35.7 (C**16**), 31.9 (C**17**), 30.3, 26.5, 26.1, 25.9 (C**17**, 2 × C**18**, C**19**); HRMS: (ESI⁺) Calculated for C₂₅H₂₈N₂NaO₂: 411.2043. Found [M + Na]⁺: 411.2050.

1-Benzyl-3-((1*R**,2*R**)-2-butylcyclopropyl)urea (*trans*-5v)



General procedure C: *tert*-Butyl (($1R^*, 2R^*$)-2-butylcyclopropyl)carbamate⁵ (427 mg, 2.00 mmol) was employed and the residue was purified by column chromatography (40% EtOAc/hexane) to provide the title compound *trans*-**5v** (463 mg, 94%) as a colorless solid; m.p. 80-83 °C (CH₂Cl₂/hexane); v_{max} / cm^{-1} : 3318 (m), 2915 (m), 1625 (s), 1570 (s), 1454 (m), 1242 (s), 1067 (m), 696 (s); ¹H NMR (CDCl₃, 400 MHz): δ 7.35-7.23 (5H, m, 2 x C**11**-<u>H</u>, 2 x C**12**-<u>H</u>, C**13**-<u>H</u>), 5.23 (1H, br. m, N<u>H</u>), 4.74 (1H, br. s, N<u>H</u>), 4.43 (2H, m, C**9**-<u>H</u>₂), 2.14 (1H, m, C**7**-<u>H</u>), 1.35-1.16 (6H, m, 2 x C**2**-<u>H</u>, 2 x C**3**-<u>H</u>, 2 x C**4**-<u>H</u>), 0.94-0.82 (4H, m, C**1**-<u>H</u>₃, C**5**-<u>H</u>), 0.69 (1H, m, 1 x C**6**-<u>H</u>), 0.51 (1H, m, 1 x C**6**-<u>H</u>); ¹³C NMR (CDCl₃, 125 MHz): δ 159.0 (C**8**), 139.4 (C**10**), 128.8, 127.7, 127.4 (C**11**, C**12**), 127.4 (C**13**), 44.4 (C**9**), 32.0 (C**4**), 31.3 (C**3**), 29.1 (C**7**), 22.5 (C**2**), 21.5 (C**5**), 14.9 (C**6**), 14.1 (C**1**); HRMS: (ESI⁺) Calculated for C₁₅H₂₂N₂NaO: 269.1624. Found [M + Na]⁺: 269.1618. *The relative stereochemistry of this compound was corroborated by nOe experiments (as indicated on the compound structure). A strong nOe was observed between C7-<u>H</u> to C4-<u>H</u>₂. No significant nOe was observed between C7-<u>H</u> and C5-<u>H</u>.*

3-Benzyl-5-butyl-1,3-diazepane-2,4-dione (9v), 1-Benzyl-6-butyl-3,6-dihydro-1*H*-1,3-diazepine-2,7-dione (8v), 3-Benzyl-6-butyl-1,3-diazepane-2,4-dione (9v') *and* 1-Benzyl-5-butyl-3,6-dihydro-1*H*-1,3-diazepine-2,7-dione (8v')



General Procedure B: Urea *trans*-5v (36.9 mg, 0.15 mmol) and [Rh(cod)₂]BARF (5.0 mol%) were employed and the reaction was stirred for 38 h at 100 °C. The crude mixture was purified by column chromatography (20% EtOAc/hexane) to yield the title compounds (28.8 mg, 70%, 3.8:1:3.4:1.9, 9v:8v:9v':8v') as a brown oil. *Repeated column chromatography allowed the partial separation of the products into two mixtures A* (15.5 mg, 38%, 4.8:1:6.0, 9v:8v:9v') and B (10.5 mg, 26%, 1.1:1:2, 9v:8v:8v'). The products were assigned by analogy to 9y, 8y, 9y' and 8y' and by 2D NMR (HSQC, HMBC).

Data for the mixture of compounds: v_{max} / cm⁻¹: 3298 (m), 2928 (m), 1705 (s), 1541 (s), 1361 (m), 1272 (m).


Data for product **9v**: *Characteristic signals only*: ¹H NMR (CDCl₃, 400 MHz): δ 8.81 (1H, br. s, N<u>H</u>), 7.33-7.24 (5H, m, 2 × C**8**-<u>H</u>, 2 × C**9**-<u>H</u>, C**10**-<u>H</u>), 4.50 (2H, m, C**6**-<u>H</u>₂), 3.93 (1H, m, 1 × C**5**-<u>H</u>), 3.66 (1H, m, 1 × C**5**-<u>H</u>), 2.60 (1H, m, C**3**-<u>H</u>), 2.20 (1H, m, 1 × C**4**-<u>H</u>), 1.68 (1H, m, 1 × C**4**-<u>H</u>), 1.50-1.24 (6H, m, C**11**-<u>H</u>₂, C**12**-<u>H</u>₂, C**13**-<u>H</u>₂), 0.93-0.89 (3H, m, C**14**-<u>H</u>₃); ¹³C NMR (CDCl₃, 100 MHz): δ 179.2 (C**2**), 44.4 (C**3**), 43.9, 43.9 (C**5**, C**6**), 24.1 (C**4**), 14.1 (C**14**); HRMS: (ESI⁺) Calculated for C₁₆H₂₂N₂NaO₂: 297.1573. Found [M + Na]⁺: 297.1583.

Data for product **8v**: *Characteristic signals only*: ¹H NMR (CDCl₃, 400 MHz): δ 7.36-7.22 (5H, m, 2 × C**8**-<u>H</u>, 2 × C**9**-<u>H</u>, C**10**-<u>H</u>), 6.10 (1H, m, C**5**-<u>H</u>), 5.14 (1H, dd, *J* = 6.5, 6.5 Hz, C**4**-<u>H</u>), 5.07 (1H, d, J = 14.5 Hz, 1 × C**6**-<u>H</u>), 4.97 (1H, d, J = 14.5 Hz, 1 × C**6**-<u>H</u>), 3.05 (1H, m, C**3**-<u>H</u>), 2.00 (1H, m, 1 × C**11**-<u>H</u>), 0.96-0.89 (3H, m, C**14**-<u>H</u>₃); ¹³C NMR (CDCl₃, 100 MHz): δ 124.6 (C**5**), 117.0 (C**4**), 48.3 (C**6**), 43.9 (C**3**), 28.4 (C**11**).

Data for product 9v': Full characterization data for compound 9v' is presented on S42.

Data for product **8v**': *Characteristic signals only*: ¹H NMR (CDCl₃, 400 MHz): δ 8.79 (1H, br. s, N<u>H</u>), 7.36-7.22 (5H, m, 2 × C**8**-<u>H</u>, 2 × C**9**-<u>H</u>, C**10**-<u>H</u>), 6.87 (1H, m, C**5**-<u>H</u>), 4.55 (2H, m, C**6**-<u>H</u>₂), 4.34 (2H, m, C**3**-<u>H</u>₂), 2.27 (2H, m, C**11**-<u>H</u>₂), 1.53 (2H, m, C**12**-<u>H</u>₂), 1.41-1.28 (2H, m, C**13**-<u>H</u>₂), 0.93 (3H, m, C**14**-<u>H</u>₃); ¹³C NMR (CDCl₃, 125 MHz): δ 138.3 (C**5**), 49.2 (C**3**), 43.9 (C**6**), 25.2 (C**11**).

1-Benzyl-3-((1S*,2S*)-2-methylcyclopropyl)urea (*trans-*5y) and 1-Benzyl-3-((1R*,2S*)-2-methylcyclopropyl)urea (*cis-*5y)




General procedure C: 1-Benzyl-3-(($1S^*$, $2S^*$)-2-methylcyclopropyl)urea⁵ (700 mg, 4.09 mmol, 5:1 d.r.) was employed and the residue was purified by column chromatography (50% EtOAc/hexane) to provide the title compound (751 mg, 90%, 8:1 d.r., *trans-5y:cis-5y*) as a pale brown solid. *The product diastereomers were inseparable by column chromatography*.

Data for the mixture of compounds: m.p. 102-104 °C (CH₂Cl₂/hexane); v_{max} / cm⁻¹: 3314 (br.), 2956 (m), 1625 (s), 1561 (s), 1246 (s), 1071 (m), 1025 (m).

Data for major product *trans*-5y: ¹H NMR (CDCl₃, 400 MHz): δ 7.37-7.25 (5H, m, 2 × C8-<u>H</u>, 2 × C9-<u>H</u>, C10-<u>H</u>), 5.16 (1H, br. s, N<u>H</u>), 4.68 (1H, br. s, N<u>H</u>), 4.46 (2H, dd, *J* = 5.5, 3.5 Hz, C6-<u>H</u>₂), 2.13 (1H, m, C4-<u>H</u>), 1.04 (3H, d, *J* = 6.0, C1-<u>H</u>₃), 0.99-0.91 (1H, m, C2-<u>H</u>), 0.73 (1H, m, 1 × C3-<u>H</u>), 0.51 (1H, m, 1 × C3-<u>H</u>); ¹³C NMR (CDCl₃, 100 MHz): δ 158.9 (C5), 139.5 (C6), 128.8, 127.5, 127.5 (C8, C9, C10), 30.1 (C4), 17.1 (C1), 16.1, 15.8 (C2, C3); HRMS: (ESI⁺) Calculated for C₁₂H₁₆N₂NaO: 227.1155. Found [M + Na]⁺: 227.1148.

Data for minor product *cis*-**5***y*: *Characteristic signals only*: ¹H NMR (400 MHz, CDCl₃): δ 5.23 (1H, br. s, N<u>H</u>), 4.58 (1H, br. s, N<u>H</u>), 2.44 (1H, m, C**4**-<u>H</u>), 1.10 (3H, d, J = 6.0, C**1**-<u>H</u>₃), 0.17 (1H, m, 1 × C**3**-<u>H</u>₂).

3-Benzyl-5-methyl-1,3-diazepane-2,4-dione (9y), 1-Benzyl-6-methyl-3,6-dihydro-1*H*-1,3-diazepine-2,7-dione (8y), 3-Benzyl-6-methyl-1,3-diazepane-2,4-dione (9y') *and* 1-Benzyl-5-methyl-3,6-dihydro-1*H*-1,3-diazepine-2,7-dione (8y')



General Procedure B: Compound *trans-5y* (30.6 mg, 0.15 mmol, 8:1 d.r.) and [Rh(cod)₂]BARF (5.0 mol%) were employed and the reaction was stirred for 69 h at 90 °C. The crude mixture was purified by column chromatography (25% EtOAc/hexane) to yield the title compounds as two separate mixtures, **A** (22.3 mg, 64%, 6.3:1:6.3, **9**y:**8**y:**9**y') and **B** (6.2 mg, 18%, 1.3:1:5.6, **9**y:**9**y':**8**y') as colorless oils. *Combined yields and product distribution* (28.5 mg, 81%, 6.9:1:6.8:2.5, **9**y:8y:**9**y':**8**y'). The compounds could not be separated by column chromatography.

Data for the mixture of compounds: v_{max} / cm^{-1} : 3301 (br.), 2964 (br.), 1708 (s), 1535 (s), 1454 (m), 1358 (m), 1258 (m).

Data for product **9y**: *Characteristic signals only*: ¹H NMR (CDCl₃, 400 MHz): δ 8.79-8.74 (1H, br. s, N<u>H</u>), 7.35-7.23 (5H, m, 2 × C**8**-<u>H</u>, 2 × C**9**-<u>H</u>, C**10**-<u>H</u>), 4.49 (2H, d, *J* = 6.0 Hz, C**6**-<u>H</u>₂), 3.93 (1H, m, 1 × C**5**-<u>H</u>), 3.66 (1H, m, 1 × C**5**-<u>H</u>), 2.75-2.63 (1H, m, C**3**-<u>H</u>), 2.29-2.21 (1H, m, 1 × C**4**-<u>H</u>), 1.64 (1H, m, 1 × C**4**-<u>H</u>), 1.23 (3H, d, *J* = 7.0 Hz, C**11**-<u>H</u>₃); ¹³C NMR (CDCl₃, 125 MHz): δ 179.6 (C**2**), 43.9 (C**5**), 38.3 (C**3**), 26.3 (C**4**), 15.5 (C**11**); HRMS: (ESI⁺) Calculated for C₁₃H₁₆N₂NaO₂: 255.1104. Found [M + Na]⁺: 255.1099. *The regiochemistry of this compound was elucidated by HMBC experiments (as indicated on the compound structure.). A strong HMBC signal was observed between C11-<u>H</u>₃ and <u>C</u>2. No measureable HMBC signal was observed between C11-<u>H</u>₃ and <u>C</u>11.*


Data for product **8y**: *Characteristic signals only*: ¹H NMR (CDCl₃, 400 MHz): δ 7.35-7.23 (5H, m, 2 × C**8**-<u>H</u>, 2 × C**9**-<u>H</u>, C**10**-<u>H</u>), 6.06 (1H, m, C**5**-<u>H</u>), 5.09 (1H, m, C**4**-<u>H</u>), 5.08 (1H, d, *J*

= 14.5 Hz, $1 \times C6-\underline{H}$), 4.96 (1H, d, J = 14.5 Hz, $1 \times C6-\underline{H}$), 3.20 (1H, m, C3- \underline{H}), 1.37 (3H, d, J = 7.0 Hz, C11- \underline{H}_3); ¹³C NMR (CDCl₃, 125 MHz): δ 124.3 (C5), 117.8 (C4), 48.3 (C6), 38.3 (C3), 14.2 (C11); HRMS: (ESI⁺) Calculated for C₁₃H₁₄N₂NaO₂: 253.0953. Found [M + Na]⁺: 253.0948. The structure of this compound was assigned by the similarity of the ¹H NMR signals of the C4 and C5 positions to related structures reported herein. The assignment was supported by 2D NMR experiments (HSQC, HMBC).

Data for product **9y**': *Characteristic signals only*: ¹H NMR (CDCl₃, 400 MHz): δ 8.79-8.74 (1H, br. s, N<u>H</u>), 7.35-7.23 (5H, m, 2 × C**8**-<u>H</u>, 2 × C**9**-<u>H</u>, C**10**-<u>H</u>), 4.50-4.48 (2H, m, C**6**-<u>H</u>₂), 4.03 (1H, dd, *J* = 11.0, 7.5 Hz, 1 × C**5**-<u>H</u>), 3.42 (1H, dd, *J* = 11.0, 6.5 Hz, 1 × C**5**-<u>H</u>), 2.72 (1H, m, 1 × C**3**-<u>H</u>), 2.43 (1H, m, C**4**-<u>H</u>), 2.25 (1H, m, 1 × C**3**-<u>H</u>), 1.15 (3H, d, *J* = 7.0 Hz, C**11**-<u>H</u>₃); ¹³C NMR (CDCl₃, 125 MHz): δ 176.8 (C**2**), 52.7 (C**5**), 41.6 (C**3**), 25.6 (C**4**), 19.2 (C**11**); HRMS: (ESI⁺) Calculated for C₁₃H₁₆N₂NaO₂: 255.1104. Found [M + Na]⁺: 255.1099. *The regiochemistry of this compound was elucidated by HMBC experiments (as indicated on the compound structure.). A strong HMBC signal was observed between C11-<u>H</u>₃ and <u>C</u>5 and between C5-<u>H</u> and <u>C</u>11. No measureable HMBC signal was observed between C11-<u>H</u>₃ and <u>C</u>2.*

Data for product **8y**': *Characteristic signals only*: ¹H NMR (CDCl₃, 400 MHz): δ 8.78 (1H, br. s, N<u>H</u>), 7.35-7.24 (5H, m, 2 × C**8**-<u>H</u>, 2 × C**9**-<u>H</u>, C**10**-<u>H</u>), 6.91 (1H, m, C**5**-<u>H</u>), 4.55 (2H, d, J = 6.0 Hz, C**6**-<u>H</u>₂), 4.33 (2H, m, C**3**-<u>H</u>₂), 1.91 (3H, m, C**11**-<u>H</u>₃); ¹³C NMR (CDCl₃, 125 MHz): δ 139.3 (C**5**), 128.8, 127.8 (C**8**, C**9**), 127.5 (C**10**), 49.1 (C**3**), 43.8 (C**6**), 11.0 (C**11**); HRMS: (ESI⁺) Calculated for C₁₃H₁₄N₂NaO₂: 253.0953. Found [M + Na]⁺: 253.0948. *The structure of this compound was assigned using 2D NMR experiments (HSQC, HMBC).*


1-Benzyl-3-((1R*,2S*)-2-cyclohexylcyclopropyl)urea (trans-5z)



General procedure C: *tert*-Butyl ((1*R**,2*S**)-2-cyclohexylcyclopropyl)carbamate⁵ (350 mg, 1.46 mmol) was employed and the residue was purified by column chromatography (40% EtOAc/hexane) to provide the title compound *trans*-5z (345 mg, 87%) as a colorless solid; m.p. 80-83 °C (CH₂Cl₂/hexane); v_{max} / cm⁻¹:3319 (br.), 2919 (m), 2847 (m), 1626 (s), 1589 (s), 1577 (s), 1446 (m), 1255 (m), 1235 (m); ¹H NMR (CDCl₃, 400 MHz): δ 7.35-7.22 (5H, m, 2 × C11-

<u>H</u>, 2 × C12-<u>H</u>, C13-<u>H</u>), 5.27 (1H, br. m, N<u>H</u>), 4.68 (1H, br. m, N<u>H</u>), 4.42 (2H, m, C9-<u>H</u>₂), 2.19 (1H, m, C7-<u>H</u>), 1.73-1.60 (5H, m, 5 × cyclohexyl C<u>H</u>), 1.18-0.94 (5H, m, 5 × cyclohexyl C<u>H</u>), 0.75 (1H, m, C4-<u>H</u>), 0.64 (1H, m, 1 × C6-<u>H</u>), 0.61-0.51 (2H, m, C5-<u>H</u>, 1 × C6-<u>H</u>); ¹³C NMR (CDCl₃, 125 MHz): δ 158.9 (C8), 139.3 (C10), 128.7, 127.8, 127.5 (C11, C12, C13), 44.5 (C9), 40.8 (C5), 32.9, 32.3 (2 × cyclohexyl <u>C</u>H₂), 28.2 (C4), 27.9 (C7), 26.4, 26.2, 26.1 (3 × cyclohexyl <u>C</u>H₂), 13.7 (C6); HRMS: (ESI⁺) Calculated for C₁₇H₂₄N₂NaO: 295.1786. Found [M + Na]⁺: 295.1775.

3-Benzyl-5-cyclohexyl-1,3-diazepane-2,4-dione (9z), 1-Benzyl-6-cyclohexyl-3,6-dihydro-1*H*-1,3-diazepine-2,7-dione (8z), 3-Benzyl-6-cyclohexyl-1,3-diazepane-2,4-dione (9z') *and* 1-Benzyl-5-cyclohexyl-3,6-dihydro-1*H*-1,3-diazepine-2,7-dione (8z')



General Procedure B: Compound *trans-5z* (40.8 mg, 0.15 mmol) and [Rh(cod)₂]BARF (7.5 mol%) were employed and the reaction was stirred for 72 h at 100 °C. The crude mixture was purified by column chromatography (25% EtOAc/hexane) to yield the title compounds (25.6 mg, 57%, 7.7:1:6:4.3, 9z:8z:9z':8z') as a brown oil; *The compounds could not be separated by column chromatography. The products were assigned by analogy to 9y, 8y, 9y' and 8y'.*

Data for the mixture of compounds: v_{max} / cm^{-1} : 3305 (br.), 2923 (m), 2853 (m), 1707 (s), 1537 (s), 1449 (m), 1360 (m), 1259 (m).


Data for product **9z**: *Characteristic signals only*: ¹H NMR (CDCl₃, 400 MHz): δ 3.87 (1H, m, 1 × C**5**-<u>H</u>), 3.66 (1H, m, 1 × C**5**-<u>H</u>); HRMS: (ESI⁺) Calculated for C₁₈H₂₄N₂NaO₂: 323.1730. Found [M + Na]⁺: 323.1739.

Data for product **8z**: *Characteristic signals only*: ¹H NMR (CDCl₃, 400 MHz): δ 6.09 (1H, m, C**5**-<u>H</u>), 5.27 (1H, t, *J* = 7.0 Hz, C**4**-<u>H</u>).

Data for product **9z**': *Characteristic signals only*: ¹H NMR (CDCl₃, 400 MHz): δ 4.05 (1H, dd, J = 11.0, 8.0 Hz, $1 \times C5-\underline{H}$), 3.43 (1H, dd, J = 11.0, 9.0 Hz, $1 \times C5-\underline{H}$), 2.62 (1H, m, $1 \times C3-\underline{H}$), 2.35 (1H, m, $1 \times C3-\underline{H}$); ¹³C NMR (CDCl₃, 125 MHz): δ 49.8 (C5), 38.2 (C3).


Data for product **8z**²: *Characteristic signals only*: ¹H NMR (CDCl₃, 400 MHz): δ 6.81 (1H, s, C**5**-<u>H</u>); ¹³C NMR (CDCl₃, 125 MHz): δ 136.8 (C**5**).

(1R*,2S*)-1,3-Dibenzyl-1-(2-butylcyclopropyl)urea (cis-5t)



General procedure A: (1R*,2S*)-N-Benzyl-2-butylcyclopropan-1-amine⁸ (508 mg, 2.50 mmol) and benzyl isocyanate (309 µL, 2.50 mmol) were employed. The crude mixture was purified by column chromatography (20% EtOAc/hexane) to yield the title compound cis-5t (814 mg, 97%) as a colorless solid; m.p.: 44-46 °C (CH₂Cl₂/hexane); v_{max} / cm⁻¹: 3356 (m), 2927 (s), 1639 (s), 1512 (s), 1495 (s), 1453 (s), 1229 (m); ¹H NMR (CDCl₃, 400 MHz): δ 7.36-7.22 (10H, m, 2 × C11-H, 2 × C12-H, C13-H, 2 × C16-H, 2 × C17-H, C18-H), 5.54 (1H, t, J = 5.5 Hz, NH), 4.86 (1H, d, J = 15.0 Hz, 1 × C14-H), 4.56-4.46 (2H, m, C9-H₂), 4.33 (1H, d, J = 15.0 Hz, $1 \times C14$ -H), 2.39 (1H, ddd, J = 7.5, 6.0, 4.5 Hz, C7-H), 1.63 (1H, m, $1 \times C4$ -H), 1.37-1.23 (4H, m, C2-H₂, C3-H₂), 1.02-0.81 (6H, m, C1-H₃, 1 × C4-H, C5-H, 1 × C6-H), 0.42 (1H, m, $1 \times C6$ -H); ¹³C NMR (CDCl₃, 100 MHz): δ 159.5 (C8), 139.6 (C10), 139.0 (C15), 128.6, 128.4, 128.1, 127.7, 127.2, 126.9 (C11, C12, C13, C16, C17, C18), 50.6 (C14), 44.9 (C9), 32.7 (C7), 31.7 (C3), 27.1 (C4), 22.5 (C2), 20.7 (C5), 14.0 (C1), 12.6 (C6); HRMS: (ESI⁺) Calculated for C₂₂H₂₉N₂O: 337.2274. Found [M + H]⁺: 337.2275. The relative stereochemistry of this compound was corroborated by nOe experiments (as indicated on the compound structure). A strong nOe was observed between C7-H to C5-H. No significant nOe was observed between $C4-\underline{H}_2$ and $C7-\underline{H}$.

1,3-Dibenzyl-5-butyl-3,6-dihydro-1*H*-1,3-diazepine-2,7-dione (8t') *and* 1,3- Dibenzyl-6-butyl-3,6-dihydro-1*H*-1,3-diazepine-2,7-dione (8t)




General Procedure B: Urea *cis*-5t (50.5 mg, 0.15 mmol) and $[Rh(cod)_2]OTf$ (7.5 mol%) were employed and the reaction was stirred for 73 h at 100 °C. The crude mixture was purified by column chromatography (50% EtOAc/hexane) to yield the title compound **8t**² (34.6 mg, 64%) as a yellow oil. Analysis of the crude reaction mixture by ¹H NMR revealed a 6:1 (**8t**²:**8t**) mixture of products.

Data for major compound **8t**': v_{max} / cm^{-1} : 1697 (m), 1647 (s), 1412 (m), 1215 (s); ¹H NMR (CDCl₃, 400 MHz): δ 7.34-7.24 (8H, m, 2 × C9-<u>H</u>, C10-<u>H</u>, 2 × C13-<u>H</u>, 2 × C14-<u>H</u>, C15-<u>H</u>), 7.08-7.06 (2H, m, 2 × C8-<u>H</u>), 5.75 (1H, t, *J* = 1.0 Hz, C5-<u>H</u>), 5.05 (2H, s, C11-<u>H</u>₂), 4.72 (2H, s, C6-<u>H</u>₂), 3.04 (2H, s, C3-<u>H</u>₂), 2.14 (2H, td, *J* = 7.0, 1.0 Hz, C16-<u>H</u>₂), 1.45-1.39 (2H, m, C17-<u>H</u>₂), 1.27-1.18 (2H, m, C18-<u>H</u>₂), 0.87 (3H, t, *J* = 7.5 Hz, C19-<u>H</u>₃); ¹³C NMR (CDCl₃, 125 MHz): δ 169.7 (C2), 154.1 (C1), 137.7 (C12), 136.3 (C7), 128.7, 128.3, 128.1, 128.0, 127.7, 127.6, 127.2 (C4, C8, C9, C10, C13, C14, C15), 124.1 (C5), 53.0 (C6), 47.5 (C11), 39.4 (C3), 33.7 (C16), 29.0 (C17), 21.9 (C18), 13.7 (C19); HRMS: (ESI⁺) Calculated for C₂₃H₂₇N₂O₂: 363.2067. Found [M + H]⁺: 363.2078.


Data for product 8t: Full characterization data for compound 8t is presented on S31-S32.

(1R*,2S*)-1-Benzyl-3-(2-butylcyclopropyl)urea (cis-5v)



General procedure A: (1*R**,2*S**)-2-Butylcyclopropan-1-amine⁸ (283 mg, 2.50 mmol) and benzyl isocyanate (309 µL, 2.50 mmol) were employed. The crude mixture was purified by column chromatography (75% EtOAc/hexane) to yield the title compound *cis*-5v (430 mg, 70%) as a colorless solid; m.p.: 66-68 °C (CH₂Cl₂/hexane); v_{max} / cm⁻¹: 3319 (s), 2927 (s), 1625 (s), 1572 (s), 1267 (s), 1240 (s); ¹H NMR (CDCl₃, 500 MHz): δ 7.31-7.22 (5H, m, 2 × C11-<u>H</u>, 2 × C12-<u>H</u>, C13-<u>H</u>), 5.44 (1H, br. s, N<u>H</u>), 4.92 (1H, br. s, N<u>H</u>), 4.40 (2H, d, *J* = 6.0 Hz, C9<u>H</u>₂), 2.45 (1H, m, C7-<u>H</u>), 1.45 (1H, m, $1 \times C4$ -<u>H</u>), 1.37-1.28 (4H, m, C2-<u>H</u>₂, C3-<u>H</u>₂), 1.19 (1H, m, $1 \times C4$ -<u>H</u>), 0.89-0.84 (4H, m, C1-<u>H</u>₃, $1 \times C6$ -<u>H</u>), 0.13 (1H, m, $1 \times C6$ -<u>H</u>); ¹³C NMR (CDCl₃, 125 MHz): δ 159.5 (C8), 139.5 (C10), 128.5, 127.4, 127.2 (C11, C12, C13), 44.2 (C9), 31.7 (C3), 27.0 (C4), 26.7 (C7), 22.6 (C2), 18.1 (C5), 14.0 (C1), 12.8 (C6); HRMS: (ESI+) Calculated for C₁₅H₂₃N₂O: 247.1805. Found [M + H]⁺: 247.1804. The relative stereochemistry of this compound was corroborated by nOe experiments (as indicated on the compound structure). A strong nOe was observed between C7-<u>H</u> to C5-<u>H</u>. No significant nOe was observed between C7-<u>H</u> and C4-<u>H</u>₂.

3-Benzyl-6-butyl-1,3-diazepane-2,4-dione (9v') *and* 3-Benzyl-5-butyl-1,3-diazepane-2,4-dione (9v)




General Procedure B: Urea *cis*-5v (37.0 mg, 0.15 mmol) and $[Rh(cod)_2]BARF$ (7.5 mol%) were employed and the reaction was stirred for 38 h at 90 °C. The crude mixture was purified by column chromatography (20% EtOAc/hexane) to yield the title compound 9v' and 9v (24.0 mg, 58%, 10:1, 9v':9v) as a yellow oil. Analysis of the crude reaction mixture by ¹H NMR revealed a 5:1 (9v':9v) mixture of products.

Data for product **9**v': v_{max} / cm^{-1} : 3304 (m), 2925 (m), 1709 (s), 1537 (s), 1260 (s); ¹H NMR (CDCl₃, 400 MHz): δ 8.75 (1H, br. s, N<u>H</u>), 7.39-7.20 (5H, m, 2 × C**8**-<u>H</u>, 2 × C**9**-<u>H</u>, C**10**-<u>H</u>), 4.50 (2H, d, *J* = 6.0 Hz, C**6**-<u>H</u>₂), 4.04 (1H, dd, *J* = 11.0, 7.5 Hz, 1 × C**5**-<u>H</u>), 3.44 (1H, dd, *J* = 11.0, 7.0 Hz, 1 × C**5**-<u>H</u>), 2.69 (1H, m, 1 × C**3**-<u>H</u>), 2.35-2.26 (2H, m, 1 × C**3**-<u>H</u>, C**4**-<u>H</u>), 1.52-1.26 (6H, m, C**11**-<u>H</u>₂, C**12**-<u>H</u>₂, C**13**-<u>H</u>₂), 0.91 (3H, t, *J* = 7.0 Hz, C**14**-<u>H</u>₃); ¹³C NMR (CDCl₃, 100 MHz): δ 176.7 (C**2**), 153.0 (C**1**), 138.3 (C**7**), 128.6, 127.6, 127.3 (C**8**, C**9**, C**10**), 51.2 (C**5**), 43.8 (C**6**), 39.9 (C**3**), 33.8 (C**11**), 30.7 (C**4**), 29.5 (C**12**), 22.6 (C**13**), 13.9 (C**14**); HRMS: (ESI⁺) Calculated for C₁₆H₂₂N₂NaO₂: 297.1573. Found [M + Na]⁺: 297.1572.

Data for product 9v: Partial characterization data for compound 9v is presented on S34-35.

(1*R**,6*S**,7*S**)-Bicyclo[4.1.0]heptan-7-amine hydroiodide (A) *and* (1*R**,6*S**,7*R**)-Bicyclo[4.1.0]heptan-7-amine hydroiodide (B)




Iodotrimethylsilane (2.45 mL, 17.2 mmol) was added to a stirred solution of methyl $((1R^*, 6S^*, 7S^*)$ -bicyclo[4.1.0]heptan-7-yl)carbamate⁹ (1.46 g, 8.61 mmol), in CH₂Cl₂ (86 mL) at r.t.. The reaction mixture was heated at reflux for 1 h before cooling to r.t.. MeOH (17 mL) was added and the reaction mixture was heated at reflux for 30 minutes before cooling to r.t. and concentrated *in vacuo*. The resulting orange solid was suspended in Et₂O (20 mL) and filtered, washing with Et₂O, to yield the title compounds (1.79 g, 87%, 3:1 d.r., **A:B**) as a brown solid. *The product diastereomers were not separable at this point*.

Data for the mixture of compounds: v_{max} / cm^{-1} : 2922 (s), 1571 (m), 1352 (m), 1066 (s); HRMS: (ESI⁺) Calculated for C₇H₁₄N: 112.1121. Found [M+H]⁺: 112.1123.

Data for major compound A: ¹H NMR (MeOD-d₄, 400 MHz): δ 2.53 (1H, t, *J* = 8.0 Hz, C4-<u>H</u>), 2.13-2.03 (2H, m, 2 × C2-<u>H</u>), 1.56-1.46 (2H, m, 2 × C2-<u>H</u>), 1.46-1.36 (2H, m, 2 × C1-<u>H</u>), 1.33-1.13 (4H, m, 2 × C1-<u>H</u>, 2 × C3-<u>H</u>); ¹³C NMR (MeOD-d₄, 100 MHz): δ 31.1 (C4), 22.0 (C1), 17.7 (C2), 11.4 (C3).

Data for major compound **B**: ¹H NMR (MeOD-d₄, 400 MHz): δ 2.36 (1H, t, *J* = 8.0 Hz, C4-<u>H</u>), 1.98-1.85 (2H, m, 2 × C2-<u>H</u>), 1.76-1.67 (2H, m, 2 × C2-<u>H</u>), 1.35-1.07 (6H, m, 4 × C1-<u>H</u>, 2 × C3-<u>H</u>); ¹³C NMR (MeOD-d₄, 100 MHz): δ 34.1 (C4), 22.4 (C2), 21.8 (C1), 17.0 (C3).

 $(1R^*, 6S^*, 7S^*)$ -*N*-Benzylbicyclo[4.1.0]heptan-7-amine (A) and $(1R^*, 6S^*, 7R^*)$ -*N*-Benzylbicyclo[4.1.0]heptan-7-amine (B)




To a stirred solution of $(1R^*, 6S^*, 7S^*)$ -bicyclo[4.1.0]heptan-7-amine hydroiodide (1.50 g, 6.3 mmol, 3:1 d.r.) in MeOH (14 mL) was added NaHCO₃ (2.11 g, 25.1 mmol) and benzaldehyde (0.58 mL, 5.65 mmol) before the reaction mixture was heated at reflux for 8 h. The reaction

mixture was cooled to 0 °C before NaBH₄ (285 mg, 7.52 mmol) was added portionwise. The reaction mixture was warmed to r.t. and stirred for 16 h. The reaction mixture was concentrated *in vacuo* before adding water (80 mL) and extracting with CH₂Cl₂ (3×30 mL). The combined organics were dried over Na₂SO₄, and concentrated *in vacuo*. The residue was purified by column chromatography (30% EtOAc/hexane) to afford diastereomer **A** (807 mg, 71%) as a pale yellow oil, and diastereomer **B** (267 mg, 23%) as a pale yellow oil.

Data for product **A**: v_{max} / cm^{-1} : 3290 (br.), 2927 (s), 1642 (s), 1542 (m), 1495 (m), 1452 (m); ¹H NMR (CDCl₃, 400 MHz): δ 7.40-7.21 (5H, m, 2 × C7-<u>H</u>, 2 × C8-<u>H</u>, C9-<u>H</u>), 3.81 (2H, s, C5-<u>H</u>₂), 2.03 (1H, t, *J* = 7.5 Hz, C4-<u>H</u>), 1.85-1.73 (2H, m, 2 × C2-<u>H</u>), 1.59-1.49 (2H, m, 2 × C2-<u>H</u>), 1.47-1.31 (2H, m, 2 × C1-<u>H</u>), 1.30-1.17 (2H, m, 2 × C1-<u>H</u>), 0.86-0.83 (2H, m, 2 × C3-<u>H</u>); ¹³C NMR (CDCl₃, 100 MHz): δ 141.4 (C6), 128.4, 128.3, 126.9 (C7, C8, C9), 54.0 (C5), 36.4 (C4), 22.8 (C1), 18.5 (C2), 12.3 (C3); HRMS: (ESI⁺) Calculated for C₁₄H₂₀N: 202.1590. Found [M+H]⁺: 202.1596. *The relative stereochemistry of this compound was corroborated by nOe experiments (as indicated on the compound structure). An nOe was observed between* C5-<u>H</u>₂ *and* C2-<u>H</u>₂. *No significant nOe was observed between* C5-<u>H</u>₂ *and* C3-<u>H</u>.

Data for product **B**: v_{max} / cm^{-1} : 2923 (s), 2850 (s), 1449 (s), 1295 (m); ¹H NMR (CDCl₃, 400 MHz): δ 7.35-7.23 (5H, m, 2 × C7-<u>H</u>, 2 × C8-<u>H</u>, C9-<u>H</u>), 3.81 (2H, s, C5-<u>H</u>₂), 1.89 – 1.80 (3H, m, 2 × C2-<u>H</u>, C4-<u>H</u>), 1.72 (1H, br. s, N<u>H</u>), 1.62-1.55 (2H, m, 2 × C2-<u>H</u>), 1.25-1.16 (2H, m, 2 × C1-<u>H</u>), 1.09-1.01 (2H, m, 2 × C2-<u>H</u>), 0.94-0.87 (2H, m, 2 × C3-<u>H</u>); ¹³C NMR (CDCl₃, 100 MHz): δ 140.7 (C6), 128.3, 128.3, 126.8 (C7, C8, C9), 53.6 (C5), 42.3 (C4), 23.0 (C2), 21.8 (C1), 18.8 (C3); HRMS: (ESI⁺) Calculated for C₁₄H₂₀N: 202.1590. Found [M + H]⁺: 202.1589.


1,3-Dibenzyl-1-((1*R**,6*S**,7*S**)-bicyclo[4.1.0]heptan-7-yl)urea (5w)



General procedure A: $(1R^*, 6S^*, 7S^*)$ -*N*-Benzylbicyclo[4.1.0]heptan-7-amine (750 mg, 3.73 mmol) was employed and the residue was purified by column chromatography (15-20% EtOAc/hexane) to provide the title compound **5w** (1.16 g, 93%) as a colorless solid; m.p.: 105-107 °C (CH₃Cl/hexane); v_{max} / cm⁻¹: 2924 (w), 1632 (s), 1504 (s), 1278 (m), 1231 (m); ¹H NMR (DMSO-d₆, 500 MHz, 70 °C): δ 7.32-7.19 (10H, m, 2 × C8-<u>H</u>, 2 × C9-<u>H</u>, C10-<u>H</u>, 2 ×


C13-<u>H</u>, 2 × C14-<u>H</u>, 2 × C15-<u>H</u>), 6.63 (1H, m, N<u>H</u>), 4.53 (2H, br. s, C11-<u>H</u>₂), 4.33 (2H, d, J = 5.9 Hz, C6-<u>H</u>₂), 2.23 (1H, t, J = 7.4 Hz, C4-<u>H</u>), 1.82 (2H, m, 2 × C2-<u>H</u>), 1.56 (2H, m, 2 × C2-<u>H</u>), 1.30-1.17 (4H, m, C1-<u>H</u>), 1.10 (2H, m, C3-<u>H</u>); ¹³C NMR (CDCl₃, 100 MHz): δ 159.2 (C5), 140.2 (C7), 138.5 (C12), 127.6, 127.5, 127.3, 126.8, 126.2, 125.9 (C8, C9, C10, C13, C14, C15), 49.8 (C11), 43.5 (C6), 34.1 (C4), 20.7 (C1), 18.5 (C2), 13.9 (C3); HRMS: (ESI⁺) Calculated for C₂₂H₂₆N₂NaO: 357.1937. Found [M + Na]⁺: 357.1937.

2,4-Dibenzyl-4,6,7,8,9,9a-hexahydro-1*H*-benzo[e][1,3]diazepine-1,3(2*H*)-dione (8w)



General Procedure B: Urea **5w** (50.2 mg, 0.15 mmol) and $[Rh(cod)_2]BARF$ (10.0 mol%) were employed and the reaction was stirred for 96 h at 90 °C. The crude mixture was purified by column chromatography (10% EtOAc/hexane) to yield the title compound **8w** (28.2 mg, 54%) as a colorless oil; v_{max} / cm^{-1} : 2934 (w), 2863 (w), 1697 (s), 1645 (s), 1404 (s); ¹H NMR (CDCl₃, 400 MHz): δ 7.33-7.24 (8H, m, 2 × C9-<u>H</u>, C10-<u>H</u>, 2 × C13-<u>H</u>, 2 × C14-<u>H</u>, C15-<u>H</u>), 7.07-7.05 (2H, m, C8-<u>H</u>), 5.82 (1H, s, C5-<u>H</u>), 5.24 (1H, d, *J* = 14.5 Hz, C11-<u>H</u>), 4.92-4.84 (2H, m, 1 × C6-<u>H</u>, 1 × C11-<u>H</u>), 4.59 (1H, d, *J* = 15.0 Hz, C6-<u>H</u>), 3.16 (1H, m, C3-<u>H</u>), 2.39 (1H, m, C16-<u>H</u>), 2.27 (1H, m, C18-<u>H</u>), 2.13 (1H, m, C16-<u>H</u>), 1.81-1.67 (3H, m, 1 × C17-<u>H</u>, C18-<u>H</u>, C19-<u>H</u>), 1.50 (1H, m, C19-<u>H</u>), 1.33 (1H, m, C17-<u>H</u>); ¹³C NMR (CDCl₃, 100 MHz): δ 171.7 (C2), 154.5 (C1), 138.0 (C12), 136.4 (C7), 128.8, 128.5, 128.4, 128.2, 127.7, 127.2 (C8, C9, C10, C13, C14, C15), 123.2 (C5), 52.8 (C6), 47.7 (C11), 41.2 (C3), 27.0 (C16), 23.1 (C17), 22.7 (C19), 22.1 (C18); HRMS: (ESI⁺) Calculated for C₂₃H₂₄N₂NaO₂: 383.1730. Found [M + Na]⁺: 383.1739.

1-Benzyl-3-((1*R**,6*S**,7*S**)-bicyclo[4.1.0]heptan-7-yl)urea (*cis*-5x) and 1-Benzyl-3-((1*R**,6*S**,7*S**)-bicyclo[4.1.0]heptan-7-yl)urea (*trans*-5x)




General procedure A: (1*R**,6*S**,7*S**)-Bicyclo[4.1.0]heptan-7-amine hydroiodide (480 mg, 3.73 mmol, 3:1 d.r.) was employed and the residue was purified by column chromatography (50% EtOAc/hexane) to provide the title compound *cis*-5x (378 mg, 77%, 4:1 d.r., *cis*-5x:*trans*-5x) as a colorless solid.

Data for the mixture of diastereomers: v_{max} / cm^{-1} : 3316 (s), 2924 (s), 2850 (s), 1629 (s), 1565 (s), 1249 (s); *m*/*z* (ESI⁺) HRMS: Calculated for C₁₅H₂₁N₂O: 245.1648. Found [M + H]⁺: 245.1646.

Data for major diastereomer *cis*-5x: ¹H NMR (CDCl₃, 400 MHz): δ 7.36-7.25 (5H, m, 2 × C8-<u>H</u>, 2 × C9-<u>H</u>, C10-<u>H</u>), 5.23 (1H, br. s, N<u>H</u>), 4.47 (2H, d, *J* = 6.0 Hz, C6-<u>H</u>₂) 2.33 (1H, t, *J* = 7.0 Hz, C4-<u>H</u>), 1.87 (2H, m, 2 × C2-<u>H</u>), 1.44-1.34 (2H, m, 2 × C2-<u>H</u>), 1.27-1.18 (4H, m, 4 × C1-<u>H</u>), 1.08-1.03 (2H, m, 2 × C3-<u>H</u>); ¹³C NMR (CDCl₃, 100 MHz): δ 159.3 (C5), 139.5 (C7), 128.7, 127.6, 127.3 (C8, C9, C10), 44.4 (C6), 29.0 (C4), 21.8 (C1), 18.0 (C2), 12.2 (C3). The relative stereochemistry of this compound was corroborated by nOe experiments (as indicated on the compound structure). A strong nOe was observed between C4-H to C3-H.

Data for minor diastereomer *trans*-5**x**: *Characteristic signals only*: ¹H NMR (CDCl₃, 400 MHz): δ 5.05 (1H, br. s, N<u>H</u>), 4.66 (1H, br. s, N<u>H</u>), 2.11 (1H, m, C4-<u>H</u>), 1.66 – 1.58 (2H, m, 2 × C2-<u>H</u>); ¹³C NMR (CDCl₃, 100 MHz): δ 159.3 (C5), 139.6 (C7), 128.7, 127.2, (Ar<u>C</u>H), 44.1 (C6), 34.0 (C4), 22.3 (C2), 21.3 (C1), 19.7 (C3).


(5aS*,9aR*)-2-Benzyloctahydro-1*H*-benzo[e][1,3]diazepine-1,3(2*H*)-dione (9x) *and* 2-Benzyl-4,5,6,7,8,9-hexahydro-1*H*-benzo[e][1,3]diazepine-1,3(2*H*)-dione (8x)



General Procedure B: Urea **5x** (36.7 mg, 0.15 mmol) and $[Rh(cod)_2]BARF (7.5 mol%)$ were employed and the reaction was stirred for 48 h at 110 °C. The crude mixture was purified by column chromatography (15-25% EtOAc/hexane) to yield the title compound **9x** (20.7 mg, 51%) as a pale brown oil and **8x** (6.8 mg, 17%) as a colorless oil. Analysis of the crude reaction mixture by ¹H NMR revealed a 3:1 (**9x:8x**) mixture of products. Data for major product **9x**: v_{max} / cm^{-1} : 3304 (m), 2929 (m), 1707 (s), 1536 (s), 1380 (s), 1247 (s); ¹H NMR (CDCl₃, 500 MHz): δ 8.76 (1H, br. s, N<u>H</u>), 7.35-7.24 (5H, m, 2 × C**8**-<u>H</u>, 2 × C**9**-<u>H</u>, C**10**-<u>H</u>), 4.53 (1H, ddd, *J* = 15.0 Hz, 5.5 Hz, 1 × C**6**-<u>H</u>), 4.47 (1H, dd, *J* = 15.0 Hz, 5.5 Hz, 1 × C**6**-<u>H</u>), 3.67 (1H, dd, *J* = 11.0 Hz, 6.0 Hz, 1 × C**5**-<u>H</u>), 3.61 (1H, dd, *J* = 11.0 Hz, 2.0 Hz, 1 × C**5**-<u>H</u>), 2.69 (1H, td, *J* = 7.0, 4.0 Hz, C**3**-<u>H</u>), 2.33 (1H, m, C**4**-<u>H</u>), 2.04 (1H, m, 1 × C**14**-<u>H</u>), 1.76 (1H, m, 1 × C**11**-<u>H</u>), 1.64-1.50 (3H, m, 1 × C**12**-<u>H</u>, 1 × C**13**-<u>H</u>, 1 × C**14**-<u>H</u>), 1.27-1.13 (3H, m, 1 × C**11**-<u>H</u>, 1 × C**12**-<u>H</u>, 1 × C**13**-<u>H</u>); ¹³C NMR (CDCl₃, 125 MHz): δ 178.1 (C**2**), 153.5 (C**1**), 138.2 (C**7**), 128.6, 127.6, 127.3 (C**8**, C**9**, C**10**), 49.3 (C**5**), 44.2 (C**3**), 43.8 (C**6**), 31.2 (C**4**), 27.7 (C**11**), 23.4 (C**12**), 22.9 (C**14**), 22.6 (C**13**); HRMS: (ESI⁺) Calculated for C₁₆H₂₀N₂NaO₂: 295.1417. Found [M + Na]⁺: 295.1424.

Data for minor product **8x**: v_{max} / cm^{-1} : 3298 (m), 2930 (m), 1699 (s), 1679 (m), 1537 (s), 1356 (s), 1250 (s); ¹H NMR (CDCl₃, 500 MHz): δ 8.75 (1H, br. s, N<u>H</u>), 7.35-7.22 (5H, m, 2 × C**8**-<u>H</u>, 2 × C**9**-<u>H</u>, C**10**-<u>H</u>), 4.53 (2H, d, *J* = 6.0 Hz, C**6**-<u>H</u>₂), 4.26 (2H, s, C**5**-<u>H</u>₂), 2.35-2.32 (2H, m, C**14**-<u>H</u>₂), 2.21-2.17 (2H, m, C**11**-<u>H</u>₂), 1.79-1.70 (4H, m, C**12**-<u>H</u>₃, C**13**-<u>H</u>₃); ¹³C NMR (CDCl₃, 125 MHz): δ 172.2 (C**2**), 154.8 (C**4**), 152.7 (C**1**), 138.5 (C**7**), 131.3 (C**3**), 128.6, 127.5, 127.2 (C**8**, C**9**, C**10**), 51.5 (C**5**), 43.6 (C**6**), 24.4 (C**14**), 21.7, 21.5 (C**12**, C**13**), 19.8 (C**11**); HRMS: (ESI⁺) Calculated for C₁₆H₁₈N₂NaO₂: 293.1260. Found [M + Na]⁺: 293.1264.

1,3-Dibenzyl-1-(2-methylprop-1-en-1-yl)urea (11b) *and* 1,3-Dibenzyl-1-(2-methylallyl)urea (11b')




To a resealable tube containing $[Rh(cod)_2]BF_4$ (4.00 mg, 0.01 mmol) and PPh₃ (7.90 mg, 0.03 mmol) under an atmosphere of argon was added urea *trans*-5s (58.9 mg, 0.20 mmol) in anhydrous toluene (2 mL). The tube was sealed and heated at 100 °C and stirred for 2 h. The mixture was cooled to r.t. and concentrated *in vacuo*. The crude mixture was purified by column chromatography (25% EtOAc/hexane) to yield the title compounds **11b** and **11b**' (50.7 mg, 86%, 2:1, **11b**:11b') as a colorless oil. *The isomers could not be separated by silica gel column chromatography*. Analysis of the crude reaction mixture by ¹H NMR revealed a 2:1 (**11b**:11b') mixture of products.

Data for the mixture of compounds: v_{max} / cm^{-1} : 3355 (m), 1643 (s), 1510 (s), 1496 (s), 1434 (m), 1264 (s); HRMS: (ESI⁺) Calculated for C₁₉H₂₃N₂O: 295.1805. Found [M + H]⁺: 295.1804.

Data for compound **11b**: ¹H NMR (CDCl₃, 400 MHz): δ 7.37-7.23 (10H, m, 2 × C**8**-<u>H</u>, 2 × C**9**-<u>H</u>, C**10**-<u>H</u>, 2 × C**13**-<u>H</u>, 2 × C**14**-<u>H</u>, C**15**-<u>H</u>), 5.67 (1H, s, C**4**-<u>H</u>), 5.11 (1H, t, *J* = 6.0 Hz, N<u>H</u>), 4.62 (2H, s, C**11**-<u>H</u>₂), 4.47 (2H, d, *J* = 6.0 Hz, C**6**-<u>H</u>₂), 1.66 (3H, s, C**1**/**2**-<u>H</u>₃), 1.50 (3H, s, C**1**/**2**-<u>H</u>₃); ¹³C NMR (CDCl₃, 100 MHz): δ 157.0 (C**5**), 139.8 (C**7**), 138.4 (C**12**), 137.9 (C**3**), 128.6, 128.5. 128.3. 127.5, 127.4, 127.0 (C**8**, C**9**, C**10**, C**13**, C**14**, C**15**), 122.3 (C**4**), 51.1 (C**11**), 44.8 (C**6**), 21.9, 17.6 (C**1**, C**2**).

Data for compound **11b**': ¹H NMR (CDCl₃, 400 MHz): δ 7.37-7.23 (10H, m, 2 × C8-<u>H</u>, 2 × C9-<u>H</u>, C10-<u>H</u>, 2 × C13-<u>H</u>, 2 × C14-<u>H</u>, C15-<u>H</u>), 4.92 (1H, s, C2-<u>H</u>), 4.89 (1H, s, C2-<u>H</u>), 4.86 (1H, br. s, N<u>H</u>), 4.54 (2H, s, C11-<u>H</u>₂), 4.46 (2H, d, *J* = 6.0 Hz, C6-<u>H</u>₂), 3.79 (2H, s, C4-<u>H</u>₂), 1.70 (3H, s, C1-<u>H</u>₃); ¹³C NMR (CDCl₃, 100 MHz): δ 158.5 (C5), 141.3 (C3), 139.6 (C7), 138.0 (C12), 128.7, 128.5, 128.4, 127.5, 127.3, 127.1 (C8, C9, C10, C13, C14, C15), 111.9 (C1), 52.7 (C4), 50.4 (C11), 44.9 (C6), 19.9 (C1).


(1S*,2R*)-1,3-Dibenzyl-1-(2-methylcyclopropyl)urea (cis-5s)



General procedure A: $(1S^*, 2R^*)$ -*N*-Benzyl-2-methylcyclopropan-1-amine⁵ (484 mg, 3.00 mmol) and benzyl isocyanate (371 µL, 3.00 mmol) were employed. The crude mixture was purified by column chromatography (30% EtOAc/hexane) to yield the title compound *cis*-5s (744 mg, 84%) as a colorless oil; v_{max} / cm⁻¹: 3326 (m), 2969 (s), 1639 (s), 1511 (s), 1453 (s), 1229 (m), 1056 (m); ¹H NMR (CDCl₃, 400 MHz): δ 7.37-7.23 (10H, m, 2 × C8-<u>H</u>, 2 × C9-<u>H</u>, C10-<u>H</u>, 2 × C13-<u>H</u>, 2 × C14-<u>H</u>, C15-<u>H</u>), 5.53 (1H, t, *J* = 5.5 Hz, N<u>H</u>), 4.88 (1H, d, *J* = 15.0 Hz, 1 × C11-<u>H</u>), 4.58-4.46 (2H, m, C6-<u>H</u>₂), 4.33 (1H, d, *J* = 15.0 Hz, 1 × C11-<u>H</u>), 2.37 (1H, ddd, *J* = 8.0, 6.0, 4.5 Hz, C4-<u>H</u>), 1.09-0.96 (4H, m, C1-<u>H</u>₃, C2-<u>H</u>), 0.89 (1H, m, 1 × C3-<u>H</u>), 0.40 (1H, m, 1 × C3-<u>H</u>); ¹³C NMR (CDCl₃, 100 MHz): δ 159.5 (C5), 139.6 (C7), 139.0 (C11), 128.6, 128.4, 128.2, 127.7, 127.2, 126.9 (C8, C9, C10, C13, C14, C15), 51.7 (C11), 45.0 (C6), 32.6 (C4), 14.7 (C2), 13.6 (C3), 12.7 (C1); HRMS: (ESI⁺) Calculated for C₁₉H₂₂N₂NaO: 317.1624.

Found $[M + Na]^+$: 317.1613. The relative stereochemistry was assigned as the opposite diastereomer of trans-5s.

(*E*)-1,3-Dibenzyl-1-(but-1-en-1-yl)urea (11a) *and* 1,3-Dibenzyl-1-(2-methylprop-1-en-1-yl)urea (11b)




To a resealable tube containing $[Rh(cod)_2]BF_4$ (4.00 mg, 0.01 mmol) and PPh₃ (7.90 mg, 0.03 mmol) under an atmosphere of argon was added urea *cis*-5s (58.9 mg, 0.20 mmol) in anhydrous toluene (2 mL). The tube was sealed and heated at 100 °C and stirred for 2 h. The mixture was cooled to r.t. and concentrated *in vacuo*. The crude mixture was purified by column chromatography (25% EtOAc/hexane) to yield the title compound **11a** (21.8 mg, 37%) as a colorless oil. Analysis of the crude reaction mixture by ¹H NMR revealed an 11:1 (**11a:11b**) mixture of products.

Data for compound **11a**: v_{max} / cm^{-1} : 3322 (s), 1628 (s), 1531 (s), 1452 (s), 1248 (s); ¹H NMR (CDCl₃, 400 MHz): δ 7.35-7.21 (10H, m, 2 × C**8**-<u>H</u>, 2× C**9**-<u>H</u>, C**10**-<u>H</u>, 2 × C**13**-<u>H</u>, 2 × C**14**-<u>H</u>, C**15**-<u>H</u>), 6.81 (1H, d, *J* = 14.0 Hz, C**4**-<u>H</u>), 5.03-4.93 (2H, m, C**3**-<u>H</u>, N<u>H</u>), 4.73 (2H, s, C**11**-<u>H</u>₂), 4.44 (2H, d, *J* = 5.5 Hz, C**6**-<u>H</u>₂), 2.02 (2H, dq, *J* = 7.0, 7.0 Hz, C**2**-<u>H</u>₂), 0.95 (3H, t, *J* = 7.0 Hz, C**1**-<u>H</u>₃); ¹³C NMR (CDCl₃, 100 MHz): δ 156.0 (C**5**), 139.1 (C**7**), 137.3 (C**12**), 128.7, 128.6, 127.5, 127.3, 127.2, 126.8, 126.5 (C**4**, C**8**, C**9**, C**10**, C**13**, C**14**, C**15**), 114.8 (C**3**), 48.7 (C**11**), 44.9 (C**6**), 23.5 (C**2**), 14.7 (C**1**); HRMS: (ESI⁺) Calculated for C₁₉H₂₃N₂O: 295.1805. Found [M + H]⁺: 295.1808.

Data for compound **11b**: *Full characterization data for compound* **11b** *is presented on S*47-*S*48.

1,3-Dibenzyl-5-methyl-3,6-dihydro-1*H*-1,3-diazepine-2,7-dione (8s') and 1,3- Dibenzyl-6methyl-3,6-dihydro-1*H*-1,3-diazepine-2,7-dione (8s)




General Procedure B: Urea *cis*-5s (44.2 mg, 0.15 mmol) and [Rh(cod)₂]BARF (7.5 mol%) were employed and the reaction was stirred for 72 h at 100 °C. The crude mixture was purified by column chromatography (25% EtOAc/hexane) to yield the title compound **8s'** (32.6 mg, 68%) as a pale yellow oil. Analysis of the crude reaction mixture by ¹H NMR revealed a 5:1 (**8s':8s**) mixture of products.

Data for major regioisomer **8s'**: v_{max} / cm^{-1} : 2971 (s), 1698 (s), 1646 (s), 1408 (s), 1214 (s); ¹H NMR (CDCl₃, 400 MHz): δ 7.35-7.21 (8H, m, 2 × C9-<u>H</u>, C10-<u>H</u>, 2 × C13-<u>H</u>, 2 × C14-<u>H</u>, C15-<u>H</u>), 7.08-7.04 (2H, m, 2 × C8-<u>H</u>), 5.78 (1H, q, *J* = 1.5 Hz, C5-<u>H</u>), 5.04 (2H, s, C11-<u>H</u>₂), 4.71 (2H, s, C6-<u>H</u>₂), 3.04 (2H, s, C3-<u>H</u>₂), 1.86 (3H, s, C16-<u>H</u>₃); ¹³C NMR (CDCl₃, 100 MHz,): δ 169.2 (C2), 154.1 (C1), 137.6 (C12), 136.3 (C7), 128.7, 128.4, 128.1, 127.7, 127.6, 127.2 (C8, C9, C10, C13, C14, C15), 124.5 (C5), 124.0 (C4), 52.9 (C6), 47.6 (C11), 40.8 (C3), 19.6 (C16); HRMS: (ESI⁺) Calculated for C₂₀H₂₀N₂NaO₂: 343.1417. Found [M + Na]⁺: 343.1408.

Data for minor regioisomer 8s: Full characterization data for compound 8s is presented on S30-S31.

3-Benzyl-6-butyl-1,3-diazepane-2,4-dione (*deutero-9v'*) and 3-Benzyl-5-butyl-1,3diazepane-2,4-dione (9v)



Deutero-cis-5v was initially prepared by repeatedly dissolving *cis*-5v in MeOD-d₄ and concentrating the resulting solution *in-vacuo*. 92% *deuterium incorporation at N1 and 90% deuterium incorporation at N2 was measured by* ¹*H NMR*.

Data for *deutero-cis-***5v**: ¹H NMR (CDCl₃, 500 MHz): δ 7.31-7.22 (5H, m, 2 × C**11**-<u>H</u>, 2 × C**12**-<u>H</u>, C**13**-<u>H</u>), 5.44 (0.08H, br. s, N<u>H</u>), 4.92 (0.10H, br. s, N<u>H</u>), 4.40 (2H, d, *J* = 6.0 Hz, C**9**-


<u>H</u>₂), 2.45 (1H, m, C**7**-<u>H</u>), 1.45 (1H, m, $1 \times C$ **4**-<u>H</u>), 1.37-1.28 (4H, m, C**2**-<u>H</u>₂, C**3**-<u>H</u>₂), 1.19 (1H, m, $1 \times C$ **4**-<u>H</u>), 0.89-0.84 (4H, m, C**1**-<u>H</u>₃, $1 \times C$ **6**-<u>H</u>), 0.13 (1H, m, $1 \times C$ **6**-<u>H</u>). *CDCl*₃ was base filtered (*K*₂*CO*₃ plug) prior to use.

General Procedure B: Urea *deutero-cis-5v* (37.0 mg, 0.150 mmol) and [Rh(cod)₂]BARF (7.5 mol%) were employed and the reaction was stirred for 43 h at 90 °C. The crude mixture was purified by column chromatography (20% EtOAc/hexane) to yield the title compound *deutero-9v*' (19.2 mg, 47%) as a yellow oil. *Analysis of the product revealed 23% and 16% deuterium incorporation at the diastereotopic C5 positions.* <5% deuterium incorporation was measured at C4. 9v could not be isolated in a pure form and therefor deuterium incorporation could not be confirmed.

Data for product *deutero*-9v': ¹H NMR (CDCl₃, 400 MHz): δ 8.75 (1H, br. s, N<u>H</u>), 7.39-7.20 (5H, m, 2 × C8-<u>H</u>, 2 × C9-<u>H</u>, C10-<u>H</u>), 4.50 (2H, d, *J* = 6.0 Hz, C6-<u>H</u>₂), 4.04 (0.81H, dd, *J* = 11.0, 7.5 Hz, 1 × C5-<u>H</u>), 3.44 (0.77H, dd, *J* = 11.0, 7.0 Hz, 1 × C5-<u>H</u>), 2.69 (1H, m, 1 × C3-<u>H</u>), 2.35-2.26 (1.96H, m, 1 × C3-<u>H</u>, C4-<u>H</u>), 1.52-1.26 (6H, m, C11-<u>H</u>₂, C12-<u>H</u>₂, C13-<u>H</u>₂), 0.91 (3H, t, *J* = 7.0 Hz, C14-<u>H</u>₃). ²H NMR (CHCl₃, 500 MHz): δ 8.74 (0.34 D, br. s, N<u>D</u>), 4.05 (0.71D, br. s, 1 × C5-<u>D</u>), 3.44 (1D, br. s, 1 × C5-<u>D</u>), 2.28 (0.04D, br. m, C4-<u>D</u>).

Data for minor compound **9v**: *Partial characterization data for compound* **9v** *is presented on S34-35*.

3-Benzyl-1,3-diazepane-2,4-dione (*deutero-9*l) and 1-Benzyl-3,6-dihydro-1*H*-1,3diazepine-2,7-dione (8l)



*Deutero-5*I was initially prepared by repeatedly dissolving 5I in MeOD-d₄ and concentrating the resulting solution *in-vacuo*. 97% *deuterium incorporation at N1 and 90% deuterium incorporation at N2 was measured by* ${}^{1}HNMR$.


Data for *deutero*-**5**I: ¹H NMR (CDCl₃, 400 MHz): δ 7.37-7.25 (2 × C**6**-<u>H</u>, 2 × C**7**-<u>H</u>, C**8**-<u>H</u>), 5.31 (0.03H, br. s, N<u>H</u>), 4.79 (0.10H, br. s, N<u>H</u>), 4.47 (2H, d, *J* = 6.0 Hz, C**4**-<u>H</u>₂), 2.46 (1H, tt,


 $J = 7.0, 3.5 \text{ Hz}, \text{C2-H}), 0.76-0.71 (2\text{H}, \text{m}, 2 \times \text{C1-H}), 0.60-0.57 (2\text{H}, \text{m}, 2 \times \text{C1-H}).$ CDCl₃ was base filtered (K₂CO₃ plug) prior to use.

General Procedure B: Urea *deutero-5***I** (28.5 mg, 0.150 mmol) and [Rh(cod)₂]BARF (5.0 mol%) were employed and the reaction was stirred for 24 h at 90 °C. The crude mixture was purified by column chromatography (30% EtOAc/hexane) to yield the title compound (20.5 mg, 63%, 2.5:1, *deutero-9***I:8I**) as a yellow oil. *Analysis of the product revealed 56% deuterium incorporation at C5, 16% at C4 and 40% at C3. No deuterium incorporation was observed in 81.*

Data for product *deutero-9*1: ¹H NMR (CDCl₃, 400 MHz): δ 8.79 (1H, br. s, N<u>H</u>), 7.35-7.21 (5H, m, 2 × C**8**-<u>H</u>, 2 × C**9**-<u>H</u>, C**10**-<u>H</u>), 4.50 (2H, d, *J* = 6.0 Hz, C**6**-<u>H</u>₂), 3.89 (1.44H, t, *J* = 7.0 Hz, C**5**-<u>H</u>₂), 2.61 (1.60H, t, *J* = 7.0 Hz, C**3**-<u>H</u>₂), 2.04 (1.84H, tt, *J* = 7.0, 7.0 Hz, C**4**-<u>H</u>₂); ²H NMR (CHCl₃, 500 MHz): δ 3.89 (0.56D, br. s, C**5**-<u>D</u>), 2.60 (0.49D, br. s, C**3**-<u>D</u>), 2.02 (0.06D, br. s, C**4**-<u>D</u>).

Data for minor compound **81**: *Full characterization data for compound* **81** *is presented on S34-35*.





To a flame-dried flask, fitted with a magnetic stirrer under an atmosphere of nitrogen, was charged cyclopropylamine (0.069 mL, 1.0 mmol) and argon sparged 1,2-DCB (5 mL, 0.2 M) followed by benzyl isocyanate (0.124 mL, 1.00 mmol). The reaction mixture was heated to 80 $^{\circ}$ C to allow complete solvation of intermediate urea **51**. Meanwhile, an oven dried reaction tube, fitted with a magnetic stirrer, was charged with [Rh(cod)₂]BARF (8.87 mg, 0.0075 mmol), and PPh₃ (3.93 mg, 0.015 mmol). The reaction tube was fitted with a rubber septum and purged with argon before the addition of the urea solution (0.75 mL, 0.015 mmol) by syringe. The resulting mixture was stirred for *ca*. 5 minutes at r.t.. The reaction tube was purged with CO and the reaction mixture was sparged with CO for 10 seconds before being heated to 100 $^{\circ}$ C for 24 h. The mixture was cooled to r.t., concentrated *in vacuo* and purified by flash column

chromatography (40% EtOAc/hexane) to yield the title compounds (18.7 mg, 57%, 6:1, **91:81**) as a yellow oil.

Selected Reaction Optimization Tables:

Initial optimization of parent substrate 5a;

	Rh source Ligand			
	Additive, CO (1 atm.) Solvent, Temp, 24 h			
5a		8a	9a	

Entry	Rh source	Ligand ^a	Solvent	Additive	Т	Yield ^b	8a:9a
	[Rh(cod ₂)]OTf		1,2-DCB				
1	(7.5 mol%)	P(3,4,5-(F) ₃ C ₆ H ₂) ₃	(0.15 M)	-	130 °C	57%	4:1
	[Rh(cod)Cl] ₂		(0.15 M) 1,2-DCB		130 °C	16%	3:1
2	(3.75 mol%)	P(3,4,5-(F) ₃ C ₆ H ₂) ₃	(0.15 M)	-			
	[Rh(cod ₂)]OTf		1,2-DCB		115 °C	70%	9:1
3	(7.5 mol%)	PPh ₃	(0.15 M)	-			
	[Rh(cod ₂)]OTf		1,2-DCB	-	100 °C	65%	27:1
4	(7.5 mol%)	PPh ₃	(0.15 M)				
_	[Rh(cod ₂)]OTf	PPh ₃	1,2-DCB	PhCO ₂ H	100 °C	77%	13:1
5	(7.5 mol%)		(0.15 M)	(100 mol%)			
6	[Rh(cod ₂)]OTf	DDI	1,2-DCB	PhCO ₂ H	100.00	76%	19:1
6	(7.5 mol%)	PPh ₃	(0.15 M)	(10 mol%)	100 °C		
7	[Rh(cod ₂)]OTf	PPh ₃	1,2-DCB	PhCO ₂ H	100 °C	76%°	19:1
7	(2.5 mol%)	F F 113	(0.2 M) (10 mol	(10 mol%)			
8	[Rh(cod ₂)]BARF	PPh ₃	1,2-DCB	PhCO ₂ H	100 °C	82%°	20:1
0	(3.5 mol%)		(0.2 M)	(15 mol%)			

^a2 eq. of ligand were employed relative to Rh loading. ^b*In-situ* yields are quoted. ^cIsolated yield.

Optimization of "challenging" substrate 5d;

Rh source Ligand Additive, CO (1 atm.) 1,2-DCB (0.2 M), 100 °C, 24 h						
	5d	T ! 19	8d	4	9d	0101
Entry	Rh source	Ligand ^a	Additive	time	Yield ^b	8d:9d
1	[Rh(cod ₂)]OTf (2.5 mol%)	PPh ₃	PhCO ₂ H (10 mol%)	24 h	23%	>15:1
2	[Rh(cod ₂)]OTf (7.5 mol%)	PPh ₃	PhCO ₂ H (10 mol%)	24 h	45%	19:1
3	[Rh(cod ₂)]BARF (3.5 mol%)	PPh ₃	PhCO ₂ H (10 mol%)	24 h	44%	17:1
4	[Rh(cod ₂)]BARF (7.5 mol%)	PPh ₃	PhCO ₂ H (10 mol%)	24 h	53%	20:1
5	[Rh(cod ₂)]BARF (7.5 mol%)	PPh ₃	PhCO ₂ H (10 mol%)	48 h	62%	18:1
6	[Rh(cod ₂)]BARF (7.5 mol%)	PPh ₃	PhCO ₂ H (15 mol%)	72 h	69%°	23:1

^a2 eq. of ligand were employed relative to Rh loading. ^b*In-situ* yields are quoted. ^cIsolated yield.

The effect of hydrogen scavengers on saturated/unsaturated product ratios;


	[Rh(cod) ₂]BARF (5.0 mol%) PPh ₃ (10 mol%) "H-scavenger" (100 mol%) CO (1 atm), 1,2-DCB (0.2 M) 90 °C, 24 h		
51	00 0,211	91	81
Entry	"H-Scavenger"	Yield ^a	Product ratio (91:81) ^c
1	No Additive	62% ^b	4:1
2	Diphenylacetylene	28%	2:1
3	Norbornene	39%	1:1.5

^a*In-situ* yields are quoted. ^bIsolated yield. ^cProduct ratios were determined by ¹H NMR analysis against an internal standard.

The presence of hydrogen scavengers was found to alter the reaction selectivity towards the unsaturated product (81).


Further Oxidative Insertion Regioselectivity Experiments

(A) Rhodacycle derived from *trans*-substituted cyclopropyl carbamate. Preferential insertion into bond a in the presence of CO ligands.⁵




(B) Rhodacycle derived from *cis*-substituted cyclopropyl carbamate. Preferential insertion


into bond b in the presence of CO ligands.8




(C) β-Hydride elimination experiment on *trans*-substituted cyclopropyl carbamate. Preferential insertion into bond a in the absence of CO ligands (procedures and data are given below).



(D) β -Hydride elimination experiment on *cis*-substituted cyclopropyl carbamate. Preferential insertion into bond b in the absence of CO ligands (procedures and data are given below).



Ethylmethyl(2-methylprop-1-en-1-yl)carbamate(14b),Ethylmethyl(2-methylallyl)carbamate(14c) and Ethylmethylcarbamate(14d)




An oven dried reaction tube, fitted with a magnetic stirrer, was charged with $[Rh(cod)_2]BF_4$ (3.1 mg, 0.0075 mmol) and PPh₃ (5.9 mg, 0.0225 mmol). The tube was fitted with a rubber septum and purged with argon. *trans*-12a⁵ (23.6 mg, 0.15 mmol, single diastereomer) in argon sparged anhydrous toluene (0.75 mL) was added *via* syringe before aging the catalyst for *ca*. 5 minutes. The reaction was heated at 100 °C with stirring for 6 h. The mixture was cooled to r.t., concentrated *in vacuo* and purified by column chromatography (5% EtOAc/hexane) to yield the title compounds (15.1 mg, 64%, 5:1, 14b:14d) as a colorless oil. *The presence of 14d is attributed to hydrolysis of enamine 14c under the reaction conditions. No linear 6*-hydride elimination products resulting from insertion into bond b were observed by NMR analysis of the crude reaction mixture.

Data for the mixture of compounds: v_{max} / cm^{-1} : 2978 (w), 1698 (s), 1447 (m), 1382 (m), 1147 (s); HRMS: (ESI⁺) Calculated for C₈H₁₅NNaO₂: 180.1000. Found [M + Na]⁺: 180.0988.

Data for major compound **14b:** ¹H NMR (CDCl₃, 400 MHz): δ 4.86 (1H, br. s, C**2**-<u>H</u>), 4.77 (1H, br. s, C**2**-<u>H</u>), 4.14 (2H, q, J = 7.0 Hz, C**6**-<u>H</u>₂), 3.80 (2H, m, C**4**-<u>H</u>₂), 2.82 (3H, m, C**8**-<u>H</u>₃), 1.67 (3H, s, C**1**-<u>H</u>₃), 1.26 (3H, m, C**7**-<u>H</u>₃); ¹³C NMR (CDCl₃, 100 MHz): δ 111.9 (C**2**), 61.4 (C**6**), 54.7 (C**4**), 33.3 (C**8**), 19.9 (C**1**), 14.9 (C**7**).


Data for major compound **14d:** *Characteristic signals only*: ¹H NMR (CDCl₃, 400 MHz): δ 2.98 (3H, s, C1-<u>H</u>₃). *Proton signals corresponding to C3 and C4 closely overlap C6 and C7 of compound 14b*.

Benzyl ((1R*,2S*)-2-butylcyclopropyl)carbamate



To a stirring solution of $(1R^*, 2S^*)$ -2-butylcyclopropan-1-amine⁸ (100 mg, 0.88 mmol) and NEt₃ (0.15 mL, 1.06 mmol) in CH₂Cl₂ (4.4 mL) was added benzyl chloroformate (150 µL, 1.06 mmol) dropwise at 0 °C over 10 minutes under an atmosphere of nitrogen. The mixture was warmed to r.t. and stirred overnight. The mixture was diluted with water (10 mL) and extracted with CH₂Cl₂ (3 × 10 mL). The organic extracts were combined, washed with brine (10 mL), dried over Na₂SO₄ and concentrated *in vacuo*. The crude mixture was purified by column chromatography (20% EtOAc/hexane) to yield the title compound (145 mg, 67%) as a colorless oil; v_{max} / cm⁻¹: 3324 (m), 1700 (s), 1525 (s), 1453 (m), 1259 (s), 1075 (s); ¹H NMR (CDCl₃, 400 MHz): δ 7.36-7.27 (5H, m, 2 × C11-H, 2 × C12-H, C13-H), 5.16-5.09 (2H, m, C9-H₂), 4.73 (1H, m, NH), 2.69 (1H, m, C7-H), 1.49-1.18 (6H, m, C2-H₂, C3-H₂, C4-H₂), 0.98-0.83 (5H, m, C1-H₃, C5-H, 1 × C6-H), 0.16 (1H, m, 1 × C6-H); ¹³C NMR (CDCl₃, 100 MHz): δ 157.3 (C8), 136.7 (C10), 128.4, 128.0 (C11, C12, C13), 66.7 (C9), 31.7 (C3), 27.6 (C7), 27.3 (C4), 22.5 (C2), 17.4 (C5), 13.9 (C1), 12.3 (C6); HRMS: (ESI⁺) Calculated for C₁₅H₂₂NO₂: 248.1645. Found [M + H]⁺: 248.1642.


Benzyl ((1R*,2S*)-2-butylcyclopropyl)(methyl)carbamate (cis-12c)



To a solution of NaH (58 mg, 2.4 mmol) in THF (1.6 mL) was added a solution of benzyl ((1*R**,2*S**)-2-butylcyclopropyl)carbamate (120 mg, 0.485 mmol) in THF (0.25 mL) and the reaction was stirred at 0 °C for 1 h. Methyl iodide (150 μ L, 2.4 mmol) was added dropwise at 0 °C and the reaction was stirred at r.t. for 18 h. Water (5 mL) was added to the reaction mixture and the solution was extracted with Et₂O (3 × 5 mL). The organic extracts were combined, washed with brine (5 mL), dried over Na₂SO₄ and concentrated *in vacuo*. The crude mixture was purified by column chromatography (10% EtOAc/hexane) to yield the title compound *cis*-**12c** (99.2 mg, 78%) as a colorless oil; v_{max} / cm⁻¹: 2927 (s), 1701 (s), 1455 (m), 1391 (s), 1344 (s), 1150 (s); ¹H NMR (CDCl₃, 400 MHz): δ 7.39-7.28 (5H, m, 2 × C**11**-H, 2 × C**12**-H, C**13**-

<u>H</u>), 5.19 -5.09 (2H, m, C9-<u>H</u>₂), 2.91 (3H, s, C14-<u>H</u>₃), 2.68 (1H, ddd, J = 7.5, 7.0, 4.5 Hz, C7-<u>H</u>), 1.58 (1H, m, 1 × C4-<u>H</u>), 1.37 – 1.25 (4H, m, C2-<u>H</u>₂, C3-<u>H</u>₂), 0.99 – 0.81 (6H, m, C1-<u>H</u>₃, 1 × C4-<u>H</u>, C5-<u>H</u>, 1 × C6-<u>H</u>), 0.32 (1H, m, 1 × C6-<u>H</u>); ¹³C NMR (CDCl₃, 100 MHz): δ 158.0 (C8), 136.9 (C10), 128.4, 127.9 (C11, C12, C13), 67.0 (C9), 35.8 (C14), 35.4 (C7), 31.7 (C3), 27.6 (C4), 22.6 (C2), 19.7 (C5), 14.1 (C1), 11.9 (C6); HRMS: (ESI⁺) Calculated for C₁₆H₂₃NNaO₂: 284.1621. Found [M + Na]⁺: 284.1623.

Benzyl (*E*)-hept-1-en-1-yl(methyl)carbamate (14e) *and* Benzyl hept-2-en-1-yl(methyl)carbamate (14f)





An oven dried reaction tube, fitted with a magnetic stirrer, was charged with $[Rh(cod)_2]BF_4$ (3.7 mg, 0.009 mmol) and PPh₃ (7.1 mg, 0.027 mmol). The tube was fitted with a rubber septum and purged with argon. Benzyl (($1R^*, 2S^*$)-2-butylcyclopropyl)(methyl)carbamate (47 mg, 0.18 mmol) in argon sparged anhydrous toluene (2 mL) was added *via* syringe before aging the catalyst for *ca*. 5 minutes. The reaction was heated at 100 °C with stirring for 3 h. The mixture was cooled to r.t., concentrated *in vacuo* and purified by column chromatography (5% EtOAc/hexane) to yield regioisomer **14e** (31.1 mg, 66%, 1:1, mixture of rotamers *A:B*) as a colorless oil and regioisomer **14f** (9.4 mg, 20%, tentatively assigned mixture of *E/Z* diastereomers) as a colorless oil.


Data for the major regioisomer **14e**: v_{max} / cm^{-1} : 2928 (m), 1693 (s), 1403 (m), 1214 (m), 1153 (s); ¹H NMR (CDCl₃, 400 MHz): δ 7.38-7.30 (5H, m, 2 × C**11**-<u>H</u>, A+B, 2 × C**12**-<u>H</u>, A+B, C**13**-<u>H</u>, A+B), 7.01 (0.50H, d, J = 14.0 Hz, C**7**-<u>H</u>, A), 6.89 (0.50H, d, J = 14.0 Hz, C**7**-<u>H</u>, B), 5.19 (2H, s, C**9**-<u>H</u>₂, A+B), 4.85 (1H, dt, J = 14.0, 7.5 Hz, C**6**-<u>H</u>, A+B), 3.07-3.05 (3H, m, C**14**-<u>H</u>₃, A+B), 2.08-1.99 (2H, m, C**5**-<u>H</u>₂, A+B), 1.40-1.25 (6H, m, C**2**-<u>H</u>₂, A+B, C**3**-H₂, A+B, C**4**-<u>H</u>₂, A+B), 0.89 (3H, t, J = 7.0 Hz, C**1**-<u>H</u>₃, A+B); ¹³C NMR (CDCl₃, 100 MHz): δ 154.3, 153.9 (C**8**, A+B), 136.4 (C**10**, A+B), 128.5, 128.2, 128.0 (C**11**, A+B, C12, A+B, C13, A+B), 127.5 (C**7**, A+B), 110.0 (C**6**, A+B), 67.8, 67.6 (C**9**, A+B), 31.5 (<u>C</u>H₂, A+B), 31.0 (C**14**, A+B), 30.2 (<u>C</u>H₂, A+B), 110.0 (C**6**, A+B), 67.8, 67.6 (C**9**, A+B), 31.5 (<u>C</u>H₂, A+B), 31.0 (C**14**, A+B), 30.2 (<u>C</u>H₂, A+B), 110.0 (C**6**, A+B), 67.8, 67.6 (C**9**, A+B), 31.5 (<u>C</u>H₂, A+B), 31.0 (C**14**, A+B), 30.2 (<u>C</u>H₂, A+B), 110.0 (C**6**, A+B), 67.8, 67.6 (C**9**, A+B), 31.5 (<u>C</u>H₂, A+B), 31.0 (C**14**, A+B), 30.2 (<u>C</u>H₂, A+B), 110.0 (C**6**, A+B), 67.8, 67.6 (C**9**, A+B), 31.5 (<u>C</u>H₂, A+B), 31.0 (C**14**, A+B), 30.2 (<u>C</u>H₂, A+B), 110.0 (C**6**, A+B), 67.8, 67.6 (C**9**, A+B), 31.5 (<u>C</u>H₂, A+B), 31.0 (C**14**, A+B), 30.2 (<u>C</u>H₂, A+B), 110.0 (C**6**, A+B), 67.8, 67.6 (C**9**, A+B), 31.5 (<u>C</u>H₂, A+B), 31.0 (C**14**, A+B), 30.2 (<u>C</u>H₂, A+B), 110.0 (C**6**, A+B), 67.8, 67.6 (C**9**, A+B), 31.5 (<u>C</u>H₂, A+B), 31.0 (C**14**, A+B), 30.2 (<u>C</u>H₂, A+B), 110.0 (C**6**, A+B), 67.8, 67.6 (C**9**, A+B), 31.5 (<u>C</u>H₂, A+B), 31.0 (C**14**, A+B), 30.2 (<u>C</u>H₂, A+B), 31.5 (<u>C</u>H₂, A+B), 31.0 (C**14**, A+B), 30.2 (<u>C</u>H₂, A+B), 31.5 (<u>C</u>H₂, A+B), 31.0 (C**14**, A+B), 30.2 (<u>C</u>H₂, A+B), 31.5 (<u>C</u>H₂, A+B), 31.5 (<u>C</u>H₂, A+B), 31.0 (C**14**, A+B), 30.2 (<u>C</u>H₂, A+B), 31.5 (<u>C</u>H₂, A+B), 31.5


A+B, C5, A+B), 22.5 (<u>C</u>H₂, A+B), 14.1 (C1, A+B). C2, C3 and C4 could not be assigned. Aldehyde peaks appear due to decomposition of the product; HRMS: (ESI⁺) Calculated for $C_{16}H_{23}NNaO_2$: 284.1621. Found [M + Na]⁺: 284.1618.


Data for the minor regioisomer **14f**: v_{max} / cm^{-1} : 2929 (m), 1705 (s), 1397 (m), 1324 (m), 1256 (s), 1136 (s); ¹H NMR (400 MHz, CDCl₃): δ 7.38-7.28 (5H, m, 2 × C**11**-<u>H</u>, 2 × C**12**-<u>H</u>, C**13**-<u>H</u>), 5.55 (1H, m, C**5**-<u>H</u>), 5.39 (1H, m, C**6**-<u>H</u>), 5.13 (2H, s, C**9**-<u>H</u>₂), 3.87-3.79 (2H, m, C**7**-<u>H</u>₂), 2.88-2.82 (3H, m, C**14**-<u>H</u>₃), 2.06-1.97 (2H, m, C**4**-<u>H</u>₂), 1.37-1.23 (4H, m, C**2**-<u>H</u>₂, C**3**-<u>H</u>₂), 0.90 (3H, t, *J* = C**1**-<u>H</u>₃); ¹³C NMR (100 MHz, CDCl₃): δ 156.2 (C**8**), 137.0 (C**10**), 133.9 (C**5**), 128.4, 127.8, 127.8 (C**11**, C**12**, C**13**), 124.6 (C**6**), 67.0 (C**9**), 50.6 (C**7**), 33.1 (C**14**), 31.8 (C**4**), 31.3 (<u>C</u>H₂), 22.2 (<u>C</u>H₂), 13.9 (C**1**). *C2 and C3 could not be assigned*; HRMS: (ESI⁺) Calculated for C₁₆H₂₃NNaO₂: 284.1621. Found [M + Na]⁺: 284.1619.

























S71




























						· · ·	· · ·			·	·	· · ·	· · ·								·	
20	210	200	190	180	170	160	150	140	130		110 1 (ppm		90	80	70	60	50	40	30	20	10	(




























S89




































S101










20 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 f1 (ppm)










S107







S109









S112





S113







S115







S117













S121














S125




























S134















S139









References

- 1. Pangborn, A. B.; Giardello, M. A.; Grubbs, R. H.; Rosen, R. K.; Timmers, F. J. *Organometallics*, **1996**, *15*, 1518.
- 2. Nicolaou, K. C.; Mathison, C. J. N.; Montagnon, T. J. Am. Chem. Soc., 2004, 126, 5192.
- 3. Shi, F.; Smith, M. R.; Maleczka, R. E. Org. Lett., 2006, 8, 1411.
- 4. Cui, W.; Loeppky, R. N. *Tetrahedron*, **2001**, *57*, 2953.
- 5. Shaw, M. H.; Croft, R. A.; Whittingham, W. G.; Bower, J. F. J. Am. Chem. Soc., 2015, 137, 8054.
- 6. Gastaldi, S.; Weinreb, S. M.; Stien, D. J. Org. Chem., 2000, 65, 3239.
- 7. Delhaye, L.; Merschaert, A.; Delbeke, P.; Briône, W. Org. Process Rev. Dev., 2007, 11, 689.
- 8. Shaw, M. H.; McCreanor, N. G.; Whittingham, W. G.; Bower, J. F. J. Am. Chem. Soc., 2015, 137, 463.
- 9. Ishikawa, S.; Sheppard, T. D.; D'Oyley, J. M.; Kamimura, A.; Motherwell, W. B. *Angew. Chem. Int. Ed.*, **2013**, *52*, 10060.